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Abstract
The medicinal uses of gold date as far back as 2500 B.C. in China. In modern times, gold has
been used in the treatment of a number of different human diseases including rheumatoid arthritis,
cancer, and viral infections. This dissertation will focus on the development of gold complexes for
the purpose of selective inhibition of HIV NCp7, a 55 amino acid zinc finger protein with two
Cys3His zinc binding domains.
NCp7 is involved in a number of viral life cycle processes including activation of reverse
transcription, integration, DNA recognition, RNA packaging, and formation of the viral envelope.
The diversity in the roles of NCp7 across the viral life cycle make it a highly attractive target for
chemical intervention. Ejection of the tetrahedrally coordinated zinc atoms, modification or
deletion of the zinc coordinating amino acids, or modification or deletion of the “essential”
tryptophan residue can result in the loss of viral infectivity. This is due to the inability of NCp7 to
recognize its “natural” substrate – polynucleic acids. Previous studies have investigated the
differences in the manner in which platinum(II), gold(I), and gold(III) complexes interact with
xix

NCp7. The platinum(II) complex [Pt(dien)(9-EtGua)]2+ interacts with the C-terminal zinc finger
of NCp7 in a non-covalent manner, through a π-π stacking interaction between the platinated 9EtGua and the “essential” tryptophan residue. The isostructural and isoelectronic complex
[Au(dien)(9-EtGua)]3+ ejects the tetrahedrally coordinated zinc atom and replaces it with a gold
atom, forming “gold fingers”. This result is consistent with the interactions of the gold(I) complex
[(PPh3)Au(9-EtGua)]+.
In order to complete the series of isoelectronic and isostructural platinum(II), palladium(II),
and gold(III) complexes with N-heterocyclic ligands and diethylenetriamine chelates, the
complexes [Au(dien)(1-MeCyt)]3+ and [Au(N-Medien)(1-MeCyt)]3+ were synthesized. These
complexes were found to dimerize the C-terminal zinc finger once the central zinc atom is ejected.
This is likely the result of a charge transfer from the 1-methylcytosine ligand to the tryptophan
residue, and is a product that was not seen as a result of interaction with the previously published
4-dimethylaminopyridine and 9-ethylguanine analogs. The 1-methylcytosine complexes also
stabilize the gold(III) oxidation state and associate with N-acetyltryptophan in a manner consistent
with the previously studied gold(III) analogs. Finally, in order to address concerns arising from
the inner filter effect, a proof of concept study using 1H-NMR spectroscopy was utilized to show
that the complex [Au(dien)(1-MeCyt)]3+ likely has a lower association constant with Nacetyltryptophan than the value determined by fluorescence quenching.
The impact of the incorporation of additional steric hindrance on the gold(III) chelate was
studied using the di-(2-picolyl)amine ligand. The gold(III) chlorides incorporating this ligand and
the centrally methylated analog were found to eject zinc from the C-terminal zinc finger of NCp7,
and the electronegativity differences between the gold(III) and platinum(II) metal centers were

xx

highlighted. The attempts to incorporate an N-heterocyclic ligand into these complexes were
unsuccessful due to the steric and electronic demands of the chelate.
The use of an organometallic chelating ligand led to the investigation of the ability of gold(III)
complexes to catalyze the arylation of zinc-coordinating cysteine residues. The complex
[AuCl2(dampa)], which had been formerly investigated as a chemotherapeutic agent due to its
structural similarities to cisplatin, was found to arylate N-acetylcysteine, glutathione, and NCp7.
The arylation was not found to be dependent on the cis- chloride ligand, as blocking that site with
the ligand triphenylphosphine did not prevent the arylation of NCp7. The X-Ray crystal structure
of the complex [AuCl(dampa)(PPh3)](PF6) was also solved. Using the advancement of the
knowledge of how the electronic and structural properties of gold(III) complexes described herein
impact interactions with NCp7, it is possible that a coordination complex that is a selective
inhibitor of NCp7 may eventually be developed.

xxi

Chapter 1: Introduction
1.1 Medicinal Uses of Gold Complexes
The earliest known use of gold in a medicinal capacity dates back as far as 2500 B.C. in China,
where gold was ingested in order to promote longevity and to cure a number of ailments such as
fainting and delirium.1,2 These treatments generally took the form of ingestion of elemental gold,
although the modern scientific community has been unable to confirm a medicinal value for this
type of treatment.3 Modern chemical development of gold-based medicine began in earnest with
the discovery that gold-cyanide inhibits the growth of Tubercule bacillus, which occurred in
1890.1,2 This discovery led to the development of gold complexes with the hope of treating
tuberculosis.3 Despite poor results in the treatment of tuberculosis in animal models, researchers
ignored these findings and carried out human trials of gold based tuberculosis treatments.4 While
these trials proved to be unsuccessful in preventing the progression of tuberculosis, trial
participants noticed an improvement in joint pain, leading to the development of gold complexes
for the treatment of rheumatoid arthritis.2,3 Two of the complexes developed for the treatment of
rheumatoid arthritis during this time, aurothiomalate and aurothioglucose (Figure 1.1), are still in
use in the clinic.2,3 In addition to clinical use for the treatment of rheumatoid arthritis,
aurothiomalate and aurothioglucose are still being investigated for new applications as medicinal
treatments. For example, aurothioglucose is being investigated as an inhibitor of thioredoxin
reductase (TrxR), and aurothiomalate is being investigated as an inhibitor of zinc finger proteins.5–
7

The development of auranofin (Figure 1.1) in the 1970s was a significant advancement in the

timeline of gold-based medicine, as it was the first orally active gold complex to be introduced
into the clinic.8 While auranofin is clinically approved for the treatment of rheumatoid arthritis, it

1

continues to be investigated for a wide range of clinical applications including inhibition of TrxR,
inhibition of angiogenesis, and antiviral applications.9–11

Figure 1.1. The structure of sodium aurothiomalate (left), aurothioglucose (middle), and
Auranofin (right).
The widespread clinical acceptance of these gold-based rheumatoid arthritis treatments, and
the discovery that auranofin was capable of inhibiting tumor cell growth both in vitro and in vivo,
led to the development of a number of gold complexes for investigation of their potential as
pharmaceuticals.2 In general, some trends in the development of these complexes can be observed,
leading most of the complexes developed to fall into two classes: analogs of the antiarthritic agents,
which are generally Au(I) complexes, and analogs of cisplatin, which make use of the isoelectronic
nature of the Pt(II) and Au(III) oxidation states.2,3,12
Many of the Au(I) complexes that have been developed were synthesized with the goal of
inhibiting tumor growth contain a gold-sulfur bond and act as inhibitors of TrxR. Many, like
auranofin, also contained phosphine ligands.2,12,13 One such example is Au-napth-1, which is an
auranofin analog containing a napthalimide ligand in place of the carbohydrate ligand. This ligand
was chosen because of the anticancer properties shown by other complexes containing
napthalimide, and likely also targets TrxR.12 More recently, the design of Au(I) complexes has
taken the complexes farther from direct analogs of auranofin. A wide variety of Au(I) complexes
containing N-heterocyclic carbene (NHC) ligands, cyclodiphosphazene ligands, phosphole
ligands, and cyclic thiourea ligands have been developed and examined for their ability to prevent
2

tumor growth and proliferation, largely through the targeting of TrxR or glutathione reductase
(GR), which causes the generation of reactive oxygen species (ROS).2,12–14 The use of NHC as a
ligand was inspired by the similarities in the donor properties of NHCs and phosphines and by the
ease with which NHCs can be modified in order to tune the lipophilic properties of the complex.15
The ease of modification of NHCs was also leveraged in the creation of [Au(NHC Nap)Cl], which
contains a naphthalene ligand capable of intercalating DNA, creating a synergistic reaction
mechanism.14

Figure 1.2. Mechanism of inhibition of Thioredoxin or Thioredoxin reductase by a gold
complex.2
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The phosphine ligand in auranofin was, at least at one time, considered critical to its function2.
This led to the development of Au(I) complexes with multiple phosphine ligands. Two such
complexes are [Au(dppe)2]+ and [Au(dnpype)2]+, which are both tetracoordinate Au(I) complexes.
[Au(dppe)2]+ was developed with the hope that the AuP4 coordination sphere would display
reduced reactivity towards thiol containing biomolecules.2,16 Additionally, the AuP4 coordination
sphere was found in [Au(dppe)2]+ was found to have increased stability relative to the twocoordinate Au(I) complexes that had been previously investigated.14 This complex showed
stability in the presence of high concentrations of glutathione (GSH) and in vivo antitumor activity
in animal models, but research on the complex as a chemotherapeutic agent was discontinued due
to high toxicity, which was thought to be caused by general membrane permeability caused by
accumulation of the complex in mitochondria.2,12,14,16 In order to reduce this toxicity, complexes
analogous to [Au(dnpype)2]+ were developed, which showed increased efficacy as a TrxR inhibitor
and decreased toxicity towards healthy cells.2,12,14,17 Other analogs of [Au(dppe)2]+ were designed,
including

[Au(dppp)(PPh3)Cl],

[Au(P(CH2OH)3)4]+,

and

the

dinuclear

complex

[{AuCl(PPh3)}2(µ2-DIPHOS)], both of which showed antitumor activity to some extent, including
[Au(P(CH2OH)3)4]+, which advanced to clinical trials.2
Despite the breadth of research that resulted from the discovery that auranofin and its analogs
were active as antitumor agents, the most commonly used inorganic anticancer agents in the clinic
continue to be cisplatin and cisplatin analogs such as carboplatin and oxaliplatin.18,19 While
development of platinum based chemotherapies continues, the isoelectronic and isostructural
relationship between Pt(II) and Au(III) has led to the investigation of Au(III) complexes as
antitumor agents.2,12,14,20 One of the first such complexes was [AuCl2(dampa)] (dampa = N,Ndimethylbenzylamine), which, like cisplatin, contains two cis chloride ligands.21 Further
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experimentation led to the development of the complexes [Au(acetato)2(dampa)] and
[Au(malonato)(dampa)], both of which showed in vivo tumor activity.22

Figure 1. 3. The structures of some gold(III) complexes investigated as anti-cancer
compounds.14

Only three other types of gold complexes have been reported to show in vivo tumor activity:
the Au(III) dithiocarbamate complexes such as [Au(DMDT)X2] and [Au(ESDT)X2](DMDT =
N,N-dimethylthiocarbamate, ESDT = ethylsarcosinedithiocarbamate, X = Cl, Br), the Au(III)
porphyrins such as [Au(III)(TPP)]+, and the Au(III) NHC complex [Au(C^N^C)(NHC)]+ (C^N^C
= 2,6-diphenylpyridine).2,12,14 Analysis of a number of dithiocarbamate complexes revealed that
the previously mentioned complexes [Au(DMDT)X2] and [Au(ESDT)X2] were the most effective
complexes in the series, and were more cytotoxic than cisplatin in both sensitive and resistant cell
lines. Activity in cell lines both sensitive and resistant towards cisplatin also proves a unique
mechanism of antitumor activity relative to cisplatin.23 A number of mono-, di-, and even trinuclear
complexes containing the tridentate chelating ligand 2,6-diphenylpyridine were also tested for
their efficacy as chemotherapeutic agents. These complexes were rationally designed due to the
5

structural similarity they share with the metallointercalator [Pt(terpy)Cl]+, and the ligands that
were investigated included N-donors, phosphines, and bridging phosphines. While the complexes
did not exhibit remarkably high cytotoxicity, the phosphine ligands improved solubility, and it was
concluded that their use could serve as a vehicle for the delivery of a cytotoxic analog.24 The
moderate success of these complexes as cytotoxic agents led to the development of the mono- and
polynuclear NHC analogs. These complexes were found to poison Topoisomerase I by stabilizing
the enzyme-DNA complex, resulting in the lead compound, [Au(C^N^C)(NHC)]+, displaying a
cytotoxic profile up to 28 times more effective than cisplatin.25 The complex is also significantly
more effective than cisplatin against cisplatin resistant cell lines, which shows the difference in
mechanism of action from cisplatin, which targets DNA forming crosslinks preventing normal
DNA transcription and replication.26 Finally, porphyrin containing complexes such as [Au(TPP)]+
were synthesized in order to improve the stability of the Au(III) oxidation state in the presence of
biologically relevant reducing agents such as glutathione.2,12,14 The meso-tetraarylporphyrin
complexes investigated exhibited both stability towards reduction and significant cytotoxicity
towards both cisplatin sensitive and resistant cell lines through dose-dependent induction of
apoptosis as determined by confocal microscopy and flow cytometry.27
Additional investigation of Au(III) complexes as isoelectronic and isostructural analogs of
cisplatin were developed in the form of Au(III) complexes with one or more Au-N bonds.12,14,28
Generally, these complexes contain a multidentate N-donor chelating ligand, and the structures of
the chelating ligands that have been investigated are diverse. One of the most important
developments from the research into the multidentate N-donor ligands is the stabilization of the
Au(III) oxidation state under physiological (reducing) conditions that was observed for complexes
such as [Au(phen)Cl2]+, [Au(terpy)Cl]2+, [AuCl(dien)]2+, [Au(cyclam)]3+, and [Au(en)2]2+ (phen =
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phenanthroline, terpy = 2,2’:6’,2’’-Terpyridine, dien = diethylenetriamine, cyclam = 1,4,8,11tetraazacyclotetradecane, en = ethylenediamine).12 The cytotoxicities of these complexes were
found to be comparable across cisplatin resistant and sensitive cell lines, and it was found by
circular dichroism and DNA melting point assays that the dien and the phen complexes caused
direct DNA damage.29

Figure 1.4. The structure of gold(III) complexes investigated for their ability to cause direct
DNA damage.29

In addition to the uses of gold complexes as treatments for rheumatoid arthritis, as in the case
of auranofin and its analogs, and as chemotherapeutic agents, such as the complexes that arose
from the investigation of Au(III) analogs of cisplatin, gold complexes have been investigated as
potential treatments for parasitic diseases and HIV/AIDS.2 The parasitic diseases for which gold
complexes have been investigated as potential treatments include malaria, leishmaniasis,
trypanomiasis, and schitsomiasis.30

7

Traditionally, chloroquine has been used to treat malaria, but the rise of chloroquine resistant
parasites has necessitated development of new treatments.31 The parasite that causes malaria in
humans, Plasmodium falciparum, possesses a thioredoxin reductase enzyme that have been
identified as a target for antimalarial intervention.32 Initial studies of gold complexes as
antimalarial agents used auranofin to target this enzyme. The other gold complexes investigated
alongside auranofin were [Au(PEt3)Cl], aurothiomalate, and [Au(Cyclam)]3+. Auranofin was the
most successful complex of the four, and the ability of auranofin to inhibit P. falciparum growth
in vitro was used to illustrate the efficacy of gold complexes as antiparasitic agents and show that
further investigation was warranted.33 One of the most successful gold-based complexes
investigated as an antimalarial agent was [Au(PPh3)(CQ)]1+, which was developed to study the
effect of modulating the electronic properties of chloroquine by binding it to gold as a ligand.
Binding chloroquine to gold was a successful strategy, as the complex showed a significant
enhancement of activity against chloroquine resistant malaria strains.34 This positive result led to
the synthesis of a series of aurated chloroquine complexes. The most effective Au(I)-chloroquine
complex against resistant parasite strains was [Au(PEt3)(CQ)]1+, but the Au(III)-chloroquine
complexes generally showed stronger activity than the Au(I) complexes.30

Figure 1.5. Inhibition of P. falciparum growth by gold complexes.33
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1.2 Zinc Finger Proteins
It has been estimated that as much as half of the total proteome is made up of proteins that bind
a metal cofactor in some capacity.35 One of the most abundant metals found in the proteome is
zinc. In humans, zinc binding proteins are encoded for by up to 10% of the total genome.36–38 The
functions of zinc as a cofactor are diverse, and include zinc in catalytic, cocatalytic, structural, and
inhibitory roles.39,40 In proteins that incorporate zinc in a structural role, a zinc(II) atom is generally
tetrahedrally coordinated to a combination of cysteine and histidine residues.39 This structural
motif was first observed in the DNA binding domain of the Xenopus laevis transcription factor
TFIIIA, where it was described as “an unusually small, self-folding domain in which Zn is a crucial
component of its tertiary structure”. This small domain was described as a “zinc finger”.41 Since
the discovery of the zinc finger structural motif, zinc fingers have been shown to be involved in a
number of biological processes. These processes include DNA recognition, RNA packaging,
transcriptional activation, apoptotic regulation, and protein assembly.36
Zinc fingers are generally divided into classes based on the zinc coordination sphere. The most
common types of zinc fingers fall into three distinct coordination spheres: Cys2His2, Cys2HisCys
(Cys3His), and Cys4.36,37,39,42,43 However, recently some additional classifications have been
discovered.37 The rationale for dividing zinc finger proteins by their zinc coordination sphere
rather than by the function of the protein or some other metric is that the reactivity of the zinc
finger protein is intimately tied to the zinc coordination sphere. Therefore, even though zinc finger
proteins are divided by the zinc coordination sphere rather than protein function, many zinc finger
proteins with similar functions have the same zinc coordination sphere.42 In addition to differences
in reactivity between the classes of zinc finger proteins, there is also a significant difference in
their abundance. One study concluded that while the human genome encodes for 4500 Cys2His2
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zinc finger domains across 564 proteins, only 17 domains across 9 proteins are encoded.44 The
inert nature of d10 zinc means that the reactivity of zinc fingers is proportional to the number of
cysteine residues – the greater the number of nucleophilic cysteine residues, the greater the
reactivity.45
Due to the large number of zinc finger proteins observed in nature and their diverse functions,
many have been studied as potential targets for chemical intervention.

Figure 1.6. Representative zinc finger motifs from each class of zinc finger protein: Cys2His2
(left), Cys3His (left center), Cys4 (right center), and mixed (right).36

Cys2His2 Zinc fingers
One of the most commonly recognized roles of Cys2His2 zinc finger proteins is that of
transcription factors.39 In fact, the first eukaryotic zinc finger to have its structure elucidated was
TFIIIA, a transcription factor in Xenopus laevis.46 TFIIIA was found to contain a repeating zinccontaining structural motif, which bound to DNA and gave rise to the term “zinc finger”.46 TFIIIA
was found to bind to both the RNA and the DNA gene that encodes for the RNA. This binding
interaction is only possible because of the specificity imparted by the zinc finger domains.47
Human transcription factor specificity protein 1 (Sp1) is another zinc finger protein containing
three Cys2His2 zinc finger domains.36,39 Sp1 was found to enhance transcription by RNA
polymerase II as much as 50 fold, and is present in quantities up to 10,000 molecules per cell.48
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Additionally, the structure of Sp1 together with its DNA binding domain was determined by NMR,
and it was found that all three zinc finger domains recognize DNA, working together to impart
selectivity for the GC box binding domain.49 Sp1 expression levels are abnormal in many types of
cancer, and higher Sp1 expression has been associated with decreased patient survival times in
some cases.50 This has led to Sp1 becoming the most widely characterized transcription factor in
mammalian cells, and makes it a highly studied target for chemotherapy development.39
Cys3His Zinc fingers
One example of a Cys3His zinc finger that has been widely studied as a chemotherapeutic agent
is poly(ADP-ribose) polymerase (PARP-1). PARP-1 catalyzes the transfer of ADP-ribose to
nuclear proteins from NAD.51 PARP-1 was found to contribute to repair of damaged DNA when
it was shown that cellular NAD content was lowered after treatment with alkylating agents or γradiation. The drop in NAD content is accompanied by an increase in PARP-1 activity.52,53

Figure 1.7. The mechanism of single-strand DNA break repair by PARP. Gold complexes have
been extensively investigated as PARP inhibitors for the purpose of treating cancer.53
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PARP-1 localizes to DNA single and double strand breaks and facilitates the assembly of repair
factors. The zinc finger domains of PARP-1 do not bind specific DNA sequences. Instead, the
structure imparted by the tetrahedral coordination of zinc recognizes damaged DNA, highlighting
the diverse set of structure-activity relationships that can be achieved using the zinc finger motif.
While the N-terminal zinc binding domain is essential to the function of PARP-1, the C-terminal
zinc binding domain was found to be less important to the function of the protein despite having a
higher affinity for DNA than the C-terminal domain, and was therefore assumed simply to assist
in the specificity for certain types of DNA strand breaks. PARP-1 does not bind to the DNA strand
breaks. Instead, the protein binds to exposed nucleobases that are present in DNA with strand
breaks, but are also present in other abnormal DNA structures, allowing PARP-1 to interact with
multiple types of damaged DNA. PARP-1 binds DNA through an interaction that has been termed
the “phosphate backbone grip” with 3-nucleotide DNA segments, allowing it to interact with
damaged DNA regardless of the DNA sequence.54 Interestingly, the repair of platinated DNA
damage by PARP-1 has also been investigated.55
Cys4 Zinc fingers
The Cys4 zinc binding motif is the most reactive traditional zinc finger structure due to the
highly electrophilic nature of the four zinc-coordinating cysteine residues. One example of the
Cys4 zinc binding motif is the human xeroderma pigmentosum group A (XPA) protein.56 XPA has
a single Cys4 zinc finger motif that acts as a recognition site for damaged DNA, and the mutation
or deletion of the zinc-coordinating cysteine residues has been shown to reduce activity. XPA is a
part of the nucleotide excision repair process, and functions by recognizing DNA damage and
recruiting other proteins in order to repair the damaged DNA.57 The increased reactivity of the
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Cys4 zinc binding motif may aid in the recognition of a number of structurally diverse patterns of
DNA damage.
Mixed Zinc Fingers
In some cases, a single protein may contain more than one type of zinc finger motif.36,37,39 One
such example is the E3 ubiquitin-protein ligase Mdm2, which contains one Cys3His zinc finger
and one Cys4 zinc finger.36 The function of an E3 is to catalyze the formation of a linkage between
Ubiquitin and its substrate, and in the case of Mdm2 this function is dependent on the C-terminal
zinc finger.58 Zinc coordination is essential for the E3 function of Mdm2, but has been found to be
non-essential in the RNA binding function.58,59
HIV-NCp7
Cys3His zinc fingers are significantly less common than Cys2His2 zinc fingers, and the
incorporation of an additional sulfur-containing cysteine into the zinc coordination sphere causes
them to be more reactive than Cys2His2 zinc fingers as well. One of the most well studied Cys3His
zinc finger proteins is the HIV nucleocapsid protein (NCp7).60,61 NCp7 has two Cys3His zinc finger
motifs, and these two zinc fingers are linked by a region of high basicity.61 The zinc in NCp7 is
bound with very high affinity (Ka = 1012 - 1014 M-1), as determined by spectrophotometric
monitoring of cobalt(II) displacement by zinc(II).62 The zinc bound protein was found to have a
high degree of flexibility, and the zinc finger motifs were found to interact weakly by 1HNOESY.63
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Figure 1.8. The structure of HIV NCp7. The C-terminal zinc finger is highlighted in red.

Like many zinc finger proteins, the primary natural substrate of NCp7 is nucleic acids. The
structure imparted by zinc coordination forms a “hydrophobic plateau”, which has a strong
influence on the binding properties of the protein.64 NCp7 binds nucleic acids in both sequencespecific and nonspecific interactions.65 In particular, NCp7 has a high affinity for guanine
residues.66 As determined by NMR, this association occurs through a π-π stacking interaction
between the nucleobases and the aromatic residues on the zinc finger motifs, F16 and W37.44,65,67
There is a very high degree of conservation, especially among the zinc-coordinating residues, and
mutations that prevent the binding of zinc result in noninfectious virions.68

Figure 1.9. The structure of NCp7 bound to an RNA substrate.36
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NCp7 is involved in a number of processes at nearly every point in the viral life cycle.69,70
These processes include reverse transcription, integration, selective packaging of viral RNA,
formation of the new viral particle, packaging RNA into a stable dimer, and protection of viral
RNA against nucleases.69 Primarily, NCp7 is a nucleic acid chaperone, meaning that it helps
nucleic acid structures to obtain their most thermodynamically stable conformations.70 As
previously mentioned, the interactions between NCp7 and its substrates can be both specific and
non-specific. This allows NCp7 to interact with virtually any oligonucleotide substrate between 5
and 8 nucleobases in length.70 This low-affinity electrostatic binding motif allows for the
protection of the viral RNA from cellular nucleases by coating the gRNA in a large number of
molecules (1500-2000) of NCp7.70 In contrast, NCp7 binds strongly and selectively to the SL3
stem-loop recognition element of the genomic Ψ-RNA, which is highly conserved across HIV-1
strains.68

Figure 1.10. NCp7 plays a part in numerous viral life cycle processes.69
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1.3 Current Treatments in HIV
There are six distinct classes of drugs currently prescribed for the treatment of HIV. These
classes are nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase
inhibitors, protease inhibitors, integrase inhibitors, and fusion inhibitors.71
Reverse transcription is the process by which double-stranded DNA is synthesized from the
viral single-stranded RNA genome. The protein that carries out reverse transcription is reverse
transcriptase (RT), which was the target of the first approved anti-AIDS drug, azidothymidine
(AZT). AZT is a nucleoside reverse transcriptase inhibitor. This class of complexes functions by
acting as a prodrug, which is converted to a dNTP analog and catalytically incorporated at the 3’end of the DNA primer synthesized by RT. Generally, this inhibits the addition of more
nucleotides. Conversely, non-nucleoside reverse transcriptase inhibitors inhibit RT by binding to
an allosteric inhibitory site on RT. Both classes of RT inhibitors suffer from drug-resistance
mechanisms. In the case of nucleoside RT inhibitors, the enzyme can also work in reverse, acting
to remove the inhibitor from the DNA strand being synthesized.72
HIV-1 protease is an enzyme that cleaves Gag and Gag-Pol polyprotein precursors in order to
produce functioning viral enzymes. Protease is a vital enzyme in the viral life cycle, and its
involvement in the production of essential enzymes makes it an attractive target for chemical
intervention. Ten protease inhibitors have been approved by the FDA, and all ten share structural
and binding similarities. All of the approved protease inhibitors bind in the active site of protease,
preventing the enzyme from binding its natural substrates by mimicking the substrate transition
state. However, the protease inhibitors suffer from high toxicity and cause significant adverse side
effects.73
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Integrase catalyzes the integration of retroviral genetic material into the DNA of the host cell.
The integrase enzyme does not have a human homolog, making it an attractive target for chemical
intervention. Many different classes of compounds have been investigated as integrase inhibitors,
including hydroxylated aromatics, diketo acids, naphthyridine carboxamides, pyrrolloquinolones,
dihydroxypyrimidine carbpxamides, and others. This research led to the development of three
FDA approved integrase inhibitors: Raltegravir, Elvitegravir, and Dolutegravir. All three of these
complexes function as integrase strand transfer inhibitors, and target the active site of integrase.74
Fusion is the process in which the virus fuses with the human cell membrane in order to gain
access to the intracellular human machinery. During fusion, a viral surface protein, HIV-1 surface
protein 120 (gp120), binds to CD4 receptors on human cells. The interaction between gp120 and
CD4, the conformation of gp120 is changed, allowing the viral glycoprotein 41 (gp41) to breach
the cell membrane, forming a pore through which the virus can enter the cell. This process is
required for viral replication, making it an attractive target for chemical intervention. The
representative fusion inhibitor is enfuvirtide, a synthetic peptide analog that binds gp41 and
disrupts its function, preventing the formation of the pore through which the virus enters the cell.
However, some patients do not tolerate the drug well, and resistance due to amino acid mutations
on gp41 that prevent drug binding has been observed.75
1.4 NCp7 as a Drug Target
The high conservation and large number of viral life cycle processes in which NCp7 is involved
make it an attractive target for chemical intervention.36,39,42,60,61,76 In fact, all known retroviruses,
with the exception of spumaretroviruses, contain at least one Cys3His zinc finger.76 The first
complexes developed to target the zinc finger motifs of viral nucleocapsid proteins were the Cnitroso complexes. The complex 3-nitrosobenzamide (NOBA) was found, using 1H-NMR, to eject
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zinc stoichiometrically from the N-terminal zinc finger of NCp7, and was found to significantly
reduce both propagation and infectivity of HIV.77 Mechanistically, NOBA acts as an electrophile.
A nucleophilic zinc-coordinating cysteine residue donates electrons to the C-nitroso group of
NOBA, resulting in the covalent modification of the cysteine thiolate, preventing zinc
coordination.78 Other organic complexes investigated for their ability to eject zinc from NCp7
include the disulfide benzamides, such as 2,2’-dithiobisbenzamide (DIBA), dithiaheterocyclic
complexes, such as 1,1-dioxide-cis-1,2-dithiane-4,5-diol (Dithiane), and α-carbonyl azoic
complexes, such as azodicarbonamide (ADA), which were all shown to inhibit NCp7 while
avoiding unwanted interactions with other zinc finger proteins.79 In general, the mechanisms by
which the organic zinc ejecting complexes react with NCp7 are thought to be the same.80 These
complexes were somewhat successful in targeting NCp7, however they suffered from inadequate
selectivity and poor effective half-life in vivo.81

Figure 1.11. Organic electrophiles that have been investigated for their ability to eject zinc from
NCp7.36
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A high throughput screening method was used in order to identify a reversible antagonist of
the NCp7-polynucleotide interaction, and fluorescein and gallein analogs were found to inhibit
oligonucleotide recognition of the protein. These complexes were shown to inhibit the activity of
NCp7 proportionally to their ability to π-π stack with the tryptophan residue on the C-terminal zinc
finger, as monitored by fluorescence quenching of tryptophan. However, these complexes also
inhibited unrelated targets. The promiscuity of these complexes was attributed to aggregate
formation, and disqualified them from significant further investigation as selective inhibitors of
NCp7.82
In order to improve on the selectivity of the electrophilic agents and develop complexes that
are capable of targeting NCp7 selectively, inorganic coordination complexes have been
investigated for their ability to act as selective agents against both NCp7 and other zinc finger
proteins. A variety of metal centers have been investigated including nickel, lead, chromium,
mercury, selenium, palladium, platinum, and gold.36,39
The current investigation of platinum, palladium, and gold complexes as zinc finger inhibitors
grew out of the success of cisplatin (cis-[PtCl2(NH3)2]) as a chemotherapeutic agent, and the
investigation of a diverse number of cisplatin analogs as treatments for both cancer and other
human diseases has been undertaken. In fact, cisplatin was found to eject zinc from a zinc finger
protein, DNA polymerase α.83 The interactions of cisplatin and transplatin with the C-terminal zinc
finger of NCp7 were investigated, and it was found that both isomers caused the ejection of the
central zinc atom as a result of a replacement of a chloride ligand by a nucleophilic cysteine thiol.84
Clearly, however, it would be impossible for a chemotherapeutic complex that functions as a DNA
damaging agent to selectively target a zinc finger protein, but this discovery offered a starting point
for further investigation.36 Generally, three methods have been proposed for targeting zinc finger
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proteins in order to treat human diseases: chelation of the central zinc atom, electrophilic attack on
the zinc-coordinating residues, and interference with the recognition of the protein’s natural
substrate – generally polynucleic acids.36

Figure 1.12. Interactions of cisplatin with the C-terminal zinc finger of NCp7 as monitored by
CD (left) and Fluorescence quenching (right).84
The π-π stacking interactions between nucleobases and the aromatic amino acids of proteins
has been extensively studied and characterized.85,86 Additionally, the realization that Nquaternization (via protonation or methylation) of a nucleobase increases the π-π stacking ability
of the nucleobase with an aromatic amino acid provided an excellent starting point for the
development of a selective NCp7 inhibitor.85,87 The enhancement of π-π stacking ability of
nucleobases was expanded to N-quaternization via metalation. The first system examined was the
[Pt(dien)(Nucleobase)]2+ system.88 The nucleobase analogs initially investigated were 9ethylguanine, 1-methylcytosine, 5’-guanosine monophosphate, and 5’-cytosine monophosphate,
and the diethylenetriamine chelate was selected in order to eliminate a labile leaving group and
ensure that only non-covalent hydrogen bonding interactions were possible. Fluorescence
quenching of tryptophan showed a significant enhancement of the association constant for the
platinated nucleobases over the free analogs, and upfield shifts of the 1H-NMR signals of N20

acetyltryptophan upon interaction with the platinated nucleobases were indicative of a π-π stacking
interaction.88
The faster hydration kinetics of palladium complexes (relative to their platinum counterparts)
led to the investigation of the Pd(II) analogs of the [Pt(dien)(Nucleobase)]2+ complexes.89 In
contrast to their Pt(II) analogs, the Pd(II) complexes formed covalent analogs with Nacetyltryptophan as shown by NMR and mass spectrometry, highlighting the increased kinetic
lability of the Pd(II) metal center.89 Theoretical studies comparing these complexes to the free
nucleobases and alkylated nucleobases showed a significant increase in the overlap between the
N-acetyltryptophan HOMO and the nucleobase LUMO upon metalation relative to the free and
alkylated nucleobases.90 The enhancement of the orbital overlap is the source of the increased
association for the metallated nucleobases over the free ligands.88–90 It was also postulated that
steric interactions with the metal center, which is relatively bulky, and rotation around the metalnucleobase bond also have an impact on the π-π stacking ability of complexes of this nature.90
Evidence for the presence of rotamers found in the platinum complexes and the great deal of steric
modification that is possible around a metal center led to the further investigation of complexes of
this form as potential selective inhibitors of NCp7.88
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Figure 1.13. N-Quaternization improves the overlap of the N-acetyltryptophan HOMO and
nucleobase LUMOs.90 1 – [Pd(dien)(1-MeCyt)]2+, 2 – [Pt(dien)(1-MeCyt)]2+, 3 – [Pd(dien)(9EtGua)]2+, 4 – [Pt(dien)(9-EtGua)]2+.

A series of trans-planar amine platinum complexes showed a strong preference for the sulfur
containing amino acid cysteine over methionine. This result is expected due to the high lability of
the chloride ligands and the high nucleophilicity of the cysteine thiol.91 The lead complex, trans[PtCl(9-EtGua)(py)2]2+, was also found to eject zinc small molecule models for the NCp7 zinc
finger.92 This complex was later found to eject zinc from the C-terminal zinc finger of NCp7. This
was determined through the use of circular dichroism, where a loss of tertiary structure indicative
of zinc ejection was observed, and by mass spectrometry, where it was shown that the complex
ejected zinc and bound 2:1 in the form [Pt(py)2]2-peptide. It was proposed that the ejection of zinc
occurred by a three step mechanism: non-covalent recognition of the protein by a π-π stacking
interaction between the tryptophan and the platinated 9-ethylguanine, displacement of the chloride
and covalent binding to a cysteine thiol, and zinc ejection concomitant with displacement of the
22

platinated nucleobase and coordination to a second cysteine thiol.93 The complex [Pt(dien)(9EtGua)]2+ was also investigated, and was found to interact noncovalently with the C-terminal zinc
finger of NCp7 – zinc ejection and covalent adduct formation were not observed.93 The 9-EtGua
and DMAP analogs were found to quench tryptophan fluorescence more effectively than a number
of other N-heterocycles, leading to the use of these N-heterocycles in many of the further
investigations into complexes containing N-heterocycles.94

Figure 1.14 The structures of platinum(II), palladium(II), and gold(III) complexes containing a
diethylenetriamine chelating ligand that were investigated as NCp7 inhibitors.94
The [Pt(dien)(9-EtGua)]3+ system was further investigated to show that DNA could be
metallated in order to disrupt the interaction between DNA and NCp7 by inhibiting the recognition
of the polynucleotide by the protein.95 The differences in the substitution kinetics between
[MCl(dien)]n+ and [MCl(terpy)]n+ (M = Pt(II), Pd(II), Au(III); terpy = 2,2’:6’,2’’-terpyridine) were
also investigated. In all cases, the labile chloride ligand resulted in covalent adduct formation with
the peptide, but it was proven that the modulation of the metal center and the chelate were a viable
platform for further investigation.96
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Figure 1.15. Interaction of [Pt(dien)(9-EtGua)]2+ with the C-terminal zinc finger of NCp7 (top).
Noncovalent adducts are not formed until MS/MS is performed (bottom).93
The noncovalent analogs formed by the complex [Pt(dien)(9-EtGua)]2+ led to the study of
analogs using the more reactive gold(III). The complexes [Au(dien)(DMAP)] 3+ and [Au(dien)(9EtGua)]3+ were found to exhibit 1H-NMR spectral differences over a range of pH values. These
spectral changes were attributed to the deprotonation of the central amine, assigned a pKa value of
3.3 for the 9-ethylguanine complex, the deprotonation of the 9-ethylguanine N1, assigned a pKa
value of 5.3, and finally dissociation of the 9-ethylguanine ligand, assigned a pKa value of 7.5.
Tryptophan fluorescence quenching was used in order to show that these complexes had a stronger
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association constant with N-acetyltryptophan than their platinum(II) and palladium(II)
counterparts. The use of the AuN4 coordination sphere was also found to stabilize the gold(III)
oxidation state relative to the AuClN3 coordination sphere, and the stabilization was found to be
proportional to the basicity of the N-heterocyclic ligand. This stabilization indicates that AuN4
complexes of this nature would be less likely to interact with sulfur-containing biomolecules, and
warranted their further investigation as selective inhibitors of NCp7.97
Complex

Ep (V)

[AuCl(dien)]2+

-0.280

[Au(dien)(9-EtGua)]3+

-0.349

[Au(dien)(DMAP)]3+

-0.328

[AuCl(N-MeDien)]2+

-0.232

[Au(N-MeDien)(9-EtGua)]3+

-0.263

[Au(N-MeDien)(DMAP)]3+

-0.238

Table 1.1. Peak potential values for the reduction of gold(III) complexes. Reduction was
determined at a platinum electrode (vs Ag/AgCl), in 50 mM phosphate buffer, 4 mM NaCl,
pH 7.4.97
In a later work, 1H-NMR studies showed a reduced reactivity with the sulfur containing amino
acids N-acetylmethionine and N-acetylcysteine for the AuN4 complexes with respect to the
AuClN4 complexes, with signals representing substitution by N-acetylmethionine appearing after
15 hours. The substitution by the thiol containing N-acetylcysteine is more rapid than the thioether
containing N-acetylmethionine. The fluorescent emission of the N-terminal zinc finger was
quenched by both the N-heterocycle containing complexes and the chloride containing complex,
indicating quenching occurred through loss of the central zinc atom and a change in peptide
structure, rather than through a π-π stacking mechanism. This change in structure was confirmed
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by circular dichroism and mass spectrometry. Interaction with the complexes caused the circular
dichroism spectrum to shift from a spectrum characteristic of zinc finger (positive band at 220 nm
and slight negative band at 195 nm) to random coil type structure (decrease in positive band
intensity, increase in negative ellipticity, slight blueshift) very rapidly. Mass spectrometric results
showed zinc ejection and formation of “gold fingers” immediately upon interaction.98
Interestingly, however, recent results obtained by EXAFS and XANES have showed that the AuN4
coordination sphere is maintained longer than previously expected.99

Figure 1.16. Differences in interactions of [AuCl(dien)]2+ and [Au(dien)(DMAP)]3+ with
NCp7 as determined by EXAFS.99

In further studies were designed to probe the ability of these complexes to prevent NCp7polynucleotide binding. Mass spectrometry of a solution of NCp7 that had been incubated with
[Au(dien)(9-EtGua)]3+ to which SL2 was added showed only uncomplexed SL2. Additionally,
mass spectrometry of a solution of complexed NCp7-SL2 to which [Au(dien)(9-EtGua)]3+ was
added showed a significant amount of free SL2, indicating that [Au(dien)(9-EtGua)]3+ was capable
of both preventing NCp7 from recognizing its natural substrate, and that the complex could disrupt
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the complex of NCp7 and its natural substrate once the complex had already formed. These mass
spectrometry results were also confirmed using an electrophoretic mobility shift assay and a
fluorescence polarization assay.100

Figure 1.17. [Au(dien)(9-EtGua)]3+ causes dissociation of the SL2-NCp7 complex.100

A similar strategy was used in the attempt to design a gold(I) complex with the ability to
selectively inhibit NCp7 as well. Complexes of this form were developed to leverage the success
of auranofin as an arthritis treatment coupled with the incorporation of the N-heterocycle
recognition element utilized in the [M(dien)(N-heterocycle)]n+ type complexes. Complexes of the
form [(PPh3)Au(N-heterocycle)]+ formed a white precipitate immediately upon interaction with
N-acetylcysteine, indicating rapid N-heterocycle displacement. Upon interaction with the Cterminal zinc finger motifs of NCp7 and Sp1, the gold was observed bound to the apopeptide with
the triphenylphosphine ligand still bound. This was the first example of a gold complex bound to
these zinc finger proteins without total ligand dissociation. Formation of gold fingers was also
observed. These results further illustrate that tuning the electronic and steric properties around the
27

metal center can have dramatic effects on the reactivity of coordination complexes with zinc finger
protein targets.101 Additional evidence that reactions with zinc finger proteins are modulated by
the metal coordination sphere was found in the complexes in which 2-mercaptothiazole and
cyanide were used as ligands in place of the N-heterocycle. In one such complex, it was found that
the phosphine ligand may dissociate first, due to the high trans effect of the 2-mercaptothiazole
ligand.102

Figure 1.18. The structures of gold(I) complexes investigated as NCp7 inhibitors.101,102

1.5 The Use of Gold Complexes to Target Zinc Finger Proteins
In addition to the study of gold complexes as selective inhibitors of NCp7, gold complexes
have also been investigated as selective inhibitors of other zinc finger proteins.103 Auranofin,
[Au(bpy)Cl2]1+, and [Au(phen)Cl2]1+ (bpy = bipyridine, phen = 1,10-phenanthroline) were
investigated for their ability to inhibit PARP-1, and were found to inhibit the protein more
effectively than the “benchmark” inhibitor, the organic complex 3-aminobenzamide. The gold(III)
complexes rapidly lost all ligands and formed “gold-finger” type structures more quickly than
auranofin, a gold(I) complex, highlighting the enhanced reactivity of the gold(III) oxidation state.
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Additionally, both the gold(I) and the gold(III) complexes formed adducts with the protein more
rapidly than the representative platinum(II) (cisplatin), ruthenium(III) (NAMI-A), and
ruthenium(II) (RAPTA-T) complexes.104
The ability of gold complexes to inhibit PARP-1 was further investigated through the synthesis
of a library of gold complexes that contained multidentate N-donor chelating ligands. It was found
that the gold complexes that displayed cytotoxic effects, such as the dinuclear [Au2{2-(2pyridyl)imidazolate}(PPh3)2]1+ also displayed the ability to inhibit PARP-1 activity in cisplatin
sensitive cells, while the complex [Au(2-phenylimidazole)(DAPTA)] (DAPTA = 3,7-diacetyl1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane), which did not display cytotoxicity was also unable
to inhibit PARP-1.105 Additionally, the analog of [Au(bpy)Cl2]1+ containing the bidentate chelating
ligand 2-((2,2’-bipyridin)-5-yl)-1H-benzimidazol-4-carboxamide was found to preferentially
target PARP-1 over the traditional target for complexes of this nature, thioredoxin reductase.106
Gold(I) complexes containing N-heterocyclic carbene ligands were also investigated for their
cytotoxic properties. These complexes were thought to interact with PARP-1 in a non-covalent
manner without loss of the gold-bound ligands.107
1.6 Gold Complexes Containing a C-Donor Ligand
Research into methods by which to further stabilize the gold(III) oxidation state has evolved
into investigation of complexes containing one or more gold-carbon bonds.14,108 While many of
the complexes containing gold-carbon bonds have been developed as chemotherapeutic agents,
with the thioredoxin/thioredoxin reductase system as the main target, some interesting protein
interactions have been discovered. A reductive elimination mechanism by which the C-donor
ligand of complexes containing 2-arylpyridine or an analog as a chelating ligand is transferred to
a cysteine thiol forming a thioether was discovered. The proof of cysteine arylation was obtained
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using a number of short cysteine-containing peptide sequences, and it was found that the reaction
proceeded over a wide range of pH and temperature. Cysteine arylation by these complexes was
also achieved on the larger proteins bovine serum albumin and human serum albumin, proving
that bioconjugation on a full protein was possible.109 This mechanism is of particular importance,
as it parallels the mechanism by which the E. coli N-Ada protein repairs DNA which has been
damaged by alkylation.110,111 While a great deal of investigation has been conducted on palladiumcatalyzed cysteine bioconjugation, the analogous gold-catalyzed reactions have been studied to a
significantly lesser extent.112–115 A recent example of a gold complex, [(Me-DalPhos)Au(R)Cl]1+
(Me-DalPhos = Ad2P(o-C6H4)NMe2, R = aryl), showed that bioconjugation of a number of
different arylating ligands is possible, including an chemotherapy drug, an affinity tag, and a
fluorescent dye. Cysteine arylation was confirmed on a short peptide sequence and on glutathione,
a target of biological relevance, by LC-MS.116

Figure 1.19. Proposed mechanism of DNA repair by the N-Ada enzyme. Alkylated DNA is
repaired by alkylation of a zinc-coordinating cysteine residue.37
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In order to probe the reactivity of complexes with a gold-carbon bond in zinc finger proteins,
the complex [Au(bnpy)Cl2] (bnpy = 2-benzylpyridine) was synthesized. The interactions of
[Au(bnpy)Cl2] were compared to the analogous N^N complexes [Au(bpy)Cl2]1+, [Au(4,4’Me2bpy)Cl2]1+, and [Au(phen)Cl2]1+. The interaction between the small molecule model Nacetylcysteine and [Au(bnpy)Cl2]1+, the cysteine arylation product was observed. It was proposed
that this arylation mechanism requires a cis orientation between the coupling partners in order for
the reductive elimination to proceed.117

Figure 1.20. General scheme of zinc finger arylation by [Au(bnpy)Cl2]. X represents an Ndonor, likely from the peptide.117
The reaction of [Au(bnpy)Cl2]1+ with the C-terminal zinc finger motif of NCp7 showed the
production of the cysteine arylation product after 48 hours, while the N^N complexes showed
products typical of interaction with a gold complex containing a labile chloride ligand. In contrast,
reaction with glutathione did not produce the cysteine arylation product, showing that the
microenvironment of the cysteine residue is important to the ability of the cysteine to be arylated.
The ability of the C-terminal zinc finger to be covalently modified by a gold complex shows the
potential for the development for a selective complex to covalently modify NCp7.117
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Figure 1.21. Interaction of [Au(bnpy)Cl2] with the C-terminal zinc finger of NCp7 after 48
hours of incubation.117

1.7 Dissertation Outline
It is the goal of this dissertation to expand on the chemistry of gold(III) complexes and their
potential uses as inhibitors of HIV NCp7 so that they might be competitive with the lead
platinum(II) complex [Pt(dien)(xanthosine)]2+ and the lead organic compounds that were
discovered to interact with NCp7 through a high throughput screening process.118,119 The
promiscuity of the previously reported [Au(dien)(N-heterocycle)]3+ complexes necessitates further
tuning of the electronic and steric environment of the AuN4 coordination sphere if a selective
inhibitor of NCp7 is to be developed. Chapter 2 discusses the attempt to develop an AuN4 complex
using the more sterically hindered chelating ligand di-(2-picolyl)amine in order to slow the
reaction with NCp7 and prevent interactions with undesirable biomolecules such as glutathione,
creating selectivity for NCp7. The gold(III) chloride complexes based on this chelate were
investigated for their interactions with NCp7 and compared with the platinum(II) analogs.
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Given the increased affinity of 1-methylcytosine for N-acetyltryptophan relative to the other
previously studied nucleobase analogs, such as 9-ethylguanine and 4-dimethylpyridine, it is natural
that the gold(III) analog of the previously studied [Pt(dien)(1-MeCyt)]2+ and [Pd(dien)(1MeCyt)]2+ be investigated. The synthesis, characterization, and interactions with the C-terminal
zinc finger of NCp7 are discussed in detail in Chapter 3.
The emergence of organometallic gold complexes has shown their potential for use in a variety
of applications. Chapter 4 aims to investigate the interactions between the organometallic complex
[AuCl2(dampa)] and biologically relevant molecules, including NCp7. The comparison of the
interactions between this complex and the similar [Au(bnpy)Cl2] are compared and contrasted. In
addition, the novel triphenylphosphine-containing complex [AuCl(dampa)(PPh3)]1+ was
investigated. The synthesis, characterization, X-ray crystal structure, and interactions of this
complex with biologically relevant molecules, including NCp7, are detailed.
Additional data, including the attempted synthesis of sterically hindered analogs of
[Au(dien)(N-heterocycle)]3+ complexes and the investigation of the binding differences between
gold(I) and gold(III) complexes with polypeptides are described in Chapter 5. Chapter 6 will detail
the recovery of residual platinum from laboratory waste. Submitted and published works are in a
format as close to the submitted format as possible.
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2.1 Abstract

Herein, we describe the interactions of [MCl(N3)]n+ complexes [M = Pt2+ (n = 1) and Au3+ (n
= 2); N3 = tridentate ancillary ligands: bpma (bis(2-pyridylmethyl)amine) or Mebpma (bis(2pyridylmethyl)methylamine)] with the C-terminal finger of HIV-1 nucleocapsid protein NCp7
(ZF2). Substitution-inert analogs [Pt(N3)L]2+ were prepared with 9-EtGua and substituted
pyridines to examine stacking interactions with tryptophan and the tryptophan-containing ZF2 and
“full” 2-finger HIVNCp7. The use of the bpma and Mebpma ligands gives slightly higher affinity
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than analogous [Pt(dien)L)]2+ complexes. The dmap-containing complexes have the greatest
affinity for the Trp residue in N-AcTrp and ZF2 peptide. Complex PtL1a has the greatest Ka when
compared with other known Pt2+ analogues; [Pt(dien)(9-EtGua)]2+ < PtL2c <[Pt(dien)(dmap)]2+<
PtL2a < PtL1a. The Ka value was also obtained for the full NCp7 peptide with PtL1a (ca.
40.6±1.0). In addition, the ESI-MS spectrum of the mixture of the ZF2 with this complex confirms
formation of a 1:1 PtL1a:ZF adduct. The reactivities of the [MCl(Mebpma)]n+ (PtL1 and AuL1)
complexes with NCp7 ZF2 (C-terminal of the NCp7 Zinc finger domain) were investigated by
ESI-MS. When compared with the known dien-containing analogs [MCl(dien)]n+, the
[MCl(Mebpma)]n+ complexes are far more reactive. The initial product of reaction of PtL1 with
ZF2 results in loss of all ligands and release of zinc to give the platinated apopeptide {PtF}. This
is in contrast to [PtCl(dien)]+ where {Pt(dien)}-peptide adducts are observed. The reaction of the
Au3+ complex AuL1 with ZF2 gives AuxFn+ species (x =1,2,4) with loss of all ligands. The
[Pt(N3)L]2+ complexes PtL1a, PtL2a, and PtL2c were inert when incubated with N-AcCys,
whereas the precursor compounds [PtCl(N3)]Cl (PtL1, N3= Mebpma; PtL2, bpma) reacted readily
with the sulfur-containing amino acid.

2.2 Introduction
The HIV nucleocapsid (NCp7) protein has an amino acid sequence highly conserved in all
HIV retrovirus subtypes. NCp7 has important roles in the viral life cycle, especially in the
assembly and reverse transcription stages.1,2 Its functions are intimately related to the protein
structure. The two zinc finger (ZF) domains in the NCp7 sequence, both of the CCHC-type, are
responsible for the protein folding that allows non-covalent interactions between amino acid
residues and the viral RNA. The π-π stacking between ZF Trp37 and the RNA guanine is one of
the most important interactions in the NCp7/RNA adduct.1,3,4 Deletion of Trp37 can lead to loss
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of protein function causing HIV inhibition.5 Due to these characteristics the NCp7 ZF has been
investigated as a target in anti HIV therapies.1,2,6–10 To enhance selectivity over other zinc fingers,
and zinc proteins in general, the aromatic amino acids Phe(ZF1) and Trp(ZF2) can be designated
as molecular targets whereby ligands (drugs) capable of π-π stacking interactions, especially with
the essential tryptophan, can inhibit DNA/RNA recognition.11,12
We are actively engaged in designing metallated-N-heterocyclic complexes targeted to
tryptophan recognition, to examine eventual interruption of the NCp7-RNA interaction.12-16
Metallation, along with protonation and alkylation, of purines and pyrimidines can increase the
affinity for π-π stacking with tryptophan over the “parent” nucleobase.13,17 The same trend is seen
for other aromatic heterocycles, e.g. 4-dimethylaminopyridine (dmap).18 For the simple amino
acid, the complexes [Pt(dien)(dmap)]2+, [Au(dien)(dmap)]3+ and [Au(N-Medien)(dmap)]3+
showed the highest association constants among other N-heterocyclic containing complexes.18,19
The use of formally substitution-inert MN4 systems is critical to this design as they enable initial
“non-covalent” recognition between the metallated nucleobases and tryptophan, followed by
nucleophilic attack of a zinc-finger cysteine at the metal site. The mechanism of action of trans[PtCl(py)2(9-EtGua)]+ (which has incipient HIV inhibitory action and ejects Zn2+ of the ZF
domain) has been proposed to involve the two steps of target recognition (Trp stacking) followed
by target “fixation” (Pt-Cys binding).14 Use of MN4 systems could allow for greater selectivity
where the Pt-N bond is more substitution-inert than its Pt-Cl counterpart.20
In this paper we describe and compare the chemistry and biology of Pt 2+ and Au3+ complexes
containing tridentate ligands based on bis(2-pyridylmethyl)amine (bpma) and further compare
their properties with the previously studied diethylenetriamine (dien) chelates. Pt2+, Pd2+ and Au3+
complexes containing the bpma ligand have been extensively studied.21–27 Herein we describe the
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reactions of formally isostructural and isoelectronic complexes [MCl(N3)]n+ (M = Pt, n = 1; Au, n
= 2; N3 = Mebpma (bis(2-pyridylmethyl)methylamine)) (Figure 2.1) with the simple amino acid
N-AcCys and the C-terminal finger NCp7(ZF2) that result in Zn2+ ejection and metallation of the
apoF2. Furthermore, we show that the stacking interactions of the platinum(II) complexes
[Pt(N3)L]2+ (L = N-heterocyclic ligand: 4-dimethylaminopyridine (dmap), 9-ethylguanine (9EtGua) and 4-methylpyridine (4-pic)) with tryptophan and the ZF2 can be tuned by judicious
choice of both tridentate ligand carrier, N3 (Mebpma instead of bpma) and L (Figure 2.1). The
properties of the bpma and Mebpma complexes are also compared with previous results using the
diethylenetriamine (dien) chelate. These results open new avenues in the search for potential and
selective candidates for HIV inhibition.
2.3 Results and Discussion
Synthesis and Characterization of the chloro-complexes [PtCl(N3)]Cl and [AuCl(N3)]Xn (N3 =
Mebpma and bpma).
[PtCl(Mebpma)]Cl (PtL1) was synthesized from cis-[PtCl2(DMSO)2] and Mebpma (bis(2pyridylmethyl)methylamine), in CH2Cl2 in 60% yield. The analogous bpma (bis(2pyridylmethyl)amine) [PtCl(bpma)]Cl (PtL2) was obtained in similar yields (98%) by the same
method. The bpma compound was previously described in the literature through synthesis in water
from [PtCl2(COD)].23,26 The analogous gold(III) complex [AuCl(Mebpma)](PF6)2 (AuL1) was
synthesized from hydrogen tetrachloroaurate hydrate and Mebpma, as previously described for the
analogous Bbpma (bis(2-pyridylmethyl)benzylamine) compound,25 and isolated in 53.5% yield. In
the case of the bpma ligand, the pale yellow [AuCl(bpma)](OTf)2 (AuL2) is thermally unstable
with a strong tendency to deprotonation of the “central” N.25 The red (AuL2) was isolated in the
amide form as the [AuCl(bpma-H)](PF6) salt as described previously.25 The related compounds
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[PtCl(dien)]Cl and [AuCl(dien)]Cl2 were also prepared for comparison following literature
methods.29,30,31

Figure 2.1. Structures of N3 ligands, the platinum(II) and gold(III) complexes investigated
in this study and of [MCl(dien)]Cln (M = Pt, n = 1; Au, n = 2).
1

H Nuclear Magnetic Resonance spectroscopy.
In the 1H NMR spectra of the two free ligands, obtained in D2O, the CH2 signal (H7) appears

as a singlet, at δ 3.55 (Mebpma) and 3.76 (bpma). After coordination, the signals are shifted
downfield and due to restricted rotation the CH2 signal becomes a doublet of doublets δ 4.60 and
5.17 for PtL1 and δ4.65 and 4.96 for PtL2. (Table 2.1, Figure 2.2). The diastereotopic protons are
designated as endo-CH and exo-CH protons (Figure 2.3a).27 The same trend is observed for the
AuL1 Mebpma complex (Figure 2.4). The spectrum, obtained in dmf-d7 due to low solubility of
the complex in water, shows a singlet at δ 3.75 (free Mebpma) and the doublet of doublets at δ
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5.47 and 6.35 (AuL1). As previously reported, the room temperature 1H NMR spectrum of AuL2
does not exhibit the split CH2 signal due to the amine-amide equilibrium and a broad singlet is
observed.25 Similarly, the amide-form [AuCl(bpma- H)](PF6) shows a sharp singlet at δ 4.40 ppm
(Figure 2.4).

Figure 2.2. 1H NMR spectra of the free ligands Mebpma and bpma and their
platinum(II) complexes PtL1 and PtL2.
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Figure 2.3. a) Designation of the endo-CH(blue) and the exo-CH(red) protons.
b) Rotamers for PtL2c.1

Figure 2.4. 1H NMR spectra for ligands and [AuCl(Mebpma)]2+ (AuL1) and [AuCl(bpmaH)]+Au(L2-H).
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Compounda

H6

H5

H4

H3

H7

H9

Mebpma

8.34

7.25

7.72

7.29

3.55

2.11

(d, 8.0)

(d, 8.0)

(td, 8.0)

(d, 8.0)

(s)

(s)

8.76

7.51

8.14

7.65

4.60/5.17

3.05

(d, 4.0)

(t, 8.0)

(t, 8.0, 4.0)

(d , 8.0) (dd, 16.0) (s)

8.35

7.24

7.72

7.30

3.76

(d, 4.0)

(t, 8.0)

(td, 8.0)

(d, 8.0)

(s)

8.53

7.21

7.98

7.52

4.65/4.96

(d, 4.0)

(t, 8.0)

(td, 8.0; 4.0)

(d, 8.0)

(dd, 16.0)

8.54

7.29

7.82

7.61

3.75

2.25

(d, 3.0)

(td, 6.0, >1.0) (td, 9.0, 3.0)

(d, 6.0)

(s)

(s)

9.13

8.13

8.72

8.32

5.47/6.35

3.94

(d, 6.0)

(t, 6.0)

(t, 6.0)

(d; 9.0)

(dd, 15.0) (s)

8.54

7.26

7.79

7.52

3.92

(d, 6.0)

(td, 6.0, 3.0)

(td, 6.0, >1.0) (d, 9.0)

(s)

7.96

8.55

8.21

4.40

(d, 6.0)

(m, 6.0)

(m, 9.0)

(d, 9.0)

(s)

9.15

8.00

8.57

8.19

6.00

PtL1

bpma

PtL2 26

Mebpma*

AuL1*

bpma *

Au(L2-H) 25* 9.14

AuL2

(dd, 6.0, >1.0) (td, 9.0, >1.0) (td, 9.0, >1.0) (d, 9.0)

-

-

-

-

-

(br s)

a: δ(Pt) for PtL1 = -2331.9 ppm; for PtL2 = -2301.8 ppm rel. to Na2PtCl6 in D2O (See
Experimental Section). *The spectra of the Pt2+ complexes were obtained in D2O and those of the
Au3+ complexes in dmf-d7. Spectra of the free ligands were obtained in both solvents for
comparison. See Figs. S1 and S3. br = broad, s = singlet, d = doublet, dd = doublet of doublets, t
= triplet, td = triplet of doublets, m = multiplet. The values in parenthesis are multiplicity and
coupling constants (Hz).
Table 2.1. 1H NMR shifts (ppm) for the [MCl(N3)]n+ complexes PtL1, PtL2, AuL1, AuL2,
Au(L2-H) and for the free N3 ligands (Mebpma and bpma).
Metal coordination leads to characteristic downfield shifts of the aromatic hydrogens of both
ligands, due to the decrease of electron density on the pyridine rings. The same occurs for the CH3
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hydrogen signal (H9) of the methylated ligand in PtL1 and AuL1 (Table 2.1). In all cases the
relative changes in shift {δ(L) - δ(ML)} are uniformly higher for the Au3+ versus Pt2+ reflecting
the greater electronegativity of the Au3+ center. The pKa for the amine-amide equilibrium in the
Au(III)-bpma compound has been estimated to be 3.5,25 comparable to that measured for
[AuCl(dien)]2+ in the range of 4.0-4.7 depending on conditions.32,33 In this respect, the behavior of
Au3+ is in stark contrast to the formally isoelectronic Pt2+ where a pKa of 11.94 has been measured
for [Pt(dien)(DMSO)]2+.34
Synthesis and Characterization of N-heterocycle-complexes [Pt(N3)L]Cl2 (N3 = Mebpma, L =
dmap; N3 = bpma, L = dmap, 4-pic or 9-EtGua).
The substitution reactions of the [MCl(N3)]n+ complexes with L = N-heterocycles were
investigated to prepare formally substitution-inert complexes of the type [Au(N3)L]3+ and
[Pt(N3)L]2+ for model studies for recognition and fixation on the zinc finger. The novel anticipated
platinum(II)

species

[Pt(Mebpma)(dmap)]Cl2

(PtL1a)

[Pt(bpma)(dmap)]Cl2

(PtL2a),

[Pt(bpma)(4-pic)]Cl2 (PtL2b) and [Pt(bpma)(9-EtGua)]Cl2 (PtL2c) were obtained in good yields
from the reactions with the respective N-heterocycles in H2O, without the necessity for activation
of the respective precursors PtL1 and PtL2 with AgNO3, (Scheme 2.1). The reaction of PtL2 with
9-EtGua and Guanosien (Guo) has been previously investigated by 1H NMR spectroscopy in
aqueous solution but the products were not isolated.27
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Scheme 2.1. Synthetic route and numbering for the [Pt(N3)L]Cl2 compounds.
The 1H NMR spectrum of the 9-EtGua-containing complex PtL2c (Table 2.2 and Figure 2.5)
evidences the presence of anti and syn rotamers related to two different spatial orientations of the
NH group which interconvert by rotation about the Pt−NH bond.27 In the 1H NMR spectra of the
dmap (PtL1a and PtL2a) and 4-pic-containing complexes (PtL2b) the H2’ and H3’ hydrogen
signals of the substituted pyridines appear as broad singlets: at δ 8.92 (H2’) and 7.67 (H3’) for
PtL2b and at around δ 8.40 (H2’) and 6.85 (H3’) for the [Pt(N3)(dmap)]2+ compounds PtL1a and
PtL2a (Table 2.2). This is due to restricted rotation of the coordinated N-heterocycle, where
different ligand conformations contribute to broaden the signals. The H2’ and H3’ signals become
narrower, more intense and slightly deshielded upon increasing the temperature to 60ºC (Figure
2.6). After cooling to 20°C (starting temperature), the NMR spectra exhibited the same profile as
before heating. These results are consistent with the refined crystal structure of the
[Pt(bpma)(py)]2+ cation where the pyridine ring is almost perpendicular to the PtN3(bpma) plane,
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with the capacity for steric hindrance – indeed broad signals of the pyridine protons were also
reported for the similar [Pt(bpma)(4-pic)]2+ cation.26

Figure 2.5. 1H NMR spectrum of PtL2c.
The
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Pt NMR spectra of all complexes show the signals expected for the [PtCl(N3)]+ and

[Pt(N3)L]2+ platinum(II) coordination spheres.35,36 For the chloride species signals are seen at δ 2331.9 ppm (PtL1) and δ -2301.8 ppm (PtL2) (See Table 1). Substitution of Pt-Cl by the N-donor
results in expected chemical shifts to δ -2413.1 (PtL1a), δ -2401.5 (PtL2a) and δ -2405.5 (PtL2b)
while the spectrum of PtL2c exhibits two signals at δ -2362.7 and δ -2379.1 ppm in accordance
with the presence of syn and anti rotamers (Table 2.2).27
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NMR Shifts (ppm), Multiplicity and Coupling Constants (Hz)
Compound

195

Pt NMR

N3 hydrogens (Mebpma and bpma)
H3

PtL2a
PtL2b

PtL2c

H5

H6

H7

H9

H2’

H3’

H6’
(H5’ for 4-pic)

3.06
(s)

8.38
(br s)

6.84
(br s)

3,15
(s)

8.46
(br s)
8.92
(br s)
H8’

6.85
(br s)
7.67
(br s)
H10’

3,15
(s)
2.58
(s)
H11’

8.51(syn) (s)
8.88 (anti)
(s)

4.22 (syn)
(q, 8.0)
4.31 (anti)
(q, 8.0)

1.48 (syn)
(t, 8.0)
1.58 (anti)
(t, 8.0)

-2413.1

7.73
(m)

8.18
(td, 8.0, 4.0)

7.43
(t, 8.0)

7.73
(m)

4.66
(d, 16.0)
5,17
(d,16.0)

-2401.5

7.67
(m)

overlapped

-

7.67
(d, 8.0)

7.37
(t, 8.0)
7.35
(t, 8.0)

7,67
(m)

-2405.5

8.13
(td, 8.0, 4.0)
8.15
(td, 8.0, 4.0)

7.56
(d, 4.0)

overlapped

-

-2362.7;
-2379.0

7.57-7.66
(m)

8.12
(t, 8.0)

7.33
(q, 8.0)

7.57-7.66
(m)

4.95
(m)

1

PtL a

H4

L hydrogens

-

Table 2.2. 195Pt and 1H NMR sifts for the [PtN3L]2+ complexes.
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Figure 2.6. 1H NMR (300 MHz) spectra of PtL1a and PtL2a at 20 and 60°C.
Attempted Synthesis of [Au(N3)L] 3+ N-heterocycle-complexes.

The analogous [Au(N3)L]3+ complexes could not be isolated as stable solids from the reactions
of AuL1 and AuL2 with the same N-heterocycles in DMF as solvent and the black products
suggested decomposition. The reactions of AuL1 and AuL2 with dmap and 9-EtGua, respectively,
were therefore monitored by 1H NMR spectroscopy, in dmf-d7 solution at room temperature, to
probe the formation of the desired products. While chemical shifts indicative of Au-9-EtGua and
Au-dmap binding were observed, multiple peaks corresponding to likely decomposition or
dissociation of the chelate rings were observed over time. The purine and substituted pyridine
ligands do remain bound even in evidence of chelate ring dissociation - the strength of the AuN(dmap) bond has been noted previously.31
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Reactivity with Biomolecules.
The structure of the HIV NCp7 peptide is shown in Scheme 2.2. In general, two aspects are
important – the recognition interaction with tryptophan and the reactivity of the [MCl(N3)] and
[M(N3)L] species toward cysteine attack. In both cases, we have used extensively the C-terminal
finger (red box) as it contains the essential tryptophan residue and is a good prognosticator of the
interaction with the full 2-finger peptide. We also compared reactivity toward the simple aminoacid N-AcetylCysteine (N-AcCys).

Scheme 2.2. Structure of the HIV NCp7 peptide.
Pt(N3)L 𝛑-𝛑 stacking interaction - Tryptophan Quenching Assay.
In earlier studies we have shown that Pt2+ and Au3+-dmap containing complexes exhibit good
affinity for N-AcTrp and the NCp7 ZF2 peptide.18,19 For the diethylenetriamine (dien) derivatives,
[Au(dien)(dmap)]3+ and [Pt(dien)(dmap)]2+ the Ka values are about 3.6 times larger than those for
the 9-EtGua-containing analogue [Pt(dien)(9-EtGua)]2+ and almost 8 times larger than the Ka for
the free dmap ligand itself. The Ka values for the [Pt(N3)L]2+ complexes described in this study
are consistent with previous trends and confirm that the dmap containing compounds (PtL1a and
PtL2a) are good tryptophan quenchers (Table 2.3). The Ka values for these complexes are 2 to 3
times larger than those for complexes containing the N-heterocycles 4-pic (PtL2b) or 9-EtGua
(PtL2c). Tryptophan affinity for PtL1a containing the Mebpma tridentate ligand is somewhat
greater than for the bpma containing analogue PtL2a and for the earlier reported Pt(II) and Au(III)62

dien complexes, with the exception of [Au(N-Medien)(dmap)]3+.18,19 Coordination to the
platinum(II) ion increases about 10 times the association constant when compared with the results
for the free dmap ligands increasing in the following order [Pt(dien)(dmap)] 2+< PtL2a < PtL1a.
Tryptophan quenching in the zinc finger ZF2 also follows this trend and the complex PtL1a
represents a significant increase over the first-published [Pt(dien)(9-EtGua)]2+.14 For PtL1a, the
value for interaction with the full NCp7 (residues 1-55) is slightly higher again, Ka = (40.6 ± 1.0)
x 103 M-1, validating the use of the C-terminal ZF2 as a general indicator of quenching efficacy.
The electronic delocalization of the dmap π electrons and ligand basicity may be responsible for
its advantage over 9-EtGua, modifying the HOMO-LUMO gap which has been considered a major
predictor of stacking affinity.17
Compound

Ka (x103) M-1
N-AcTrp

ZF2

PtL1a

32.8 ± 2.0

33.1 ± 3.7 (40.6 ± 1.0)*

PtL2a

28.3 ± 3.4

30.7 ± 4.6

PtL2b

13.4 ± 2.6

17.4 ± 4.7

PtL2c

11.7 ± 0.7

15.9 ± 1.5

[Pt(dien)(dmap)] 2+

25.0 ± 0.9a

28.1 ± 1.8a

[Au(dien)(dmap)] 3+

25.5 ± 0.3a

-

[Pt(dien)(9-EtGua)] 2+ 6.88 ± 0.3a
dmap

7.5a

3.19 ± 0.01b -

References: a18 and b15. *Values in parentheses were obtained with the full NCp7.
Table 2.3. Association constants for N-heterocycle compounds with the N-AcTrp and NCp7
ZF2.
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Studies of the reactivity of platinum(II) complexes with N-acetylcysteine.
The covalent interaction with zinc fingers is considered to occur through electrophilic attack
on the ZF cysteine residues. To examine the reactivity pattern, the reactions of the precursors PtL1
and PtL2 and of [Pt(N3)L]Cl2 (PtL1a, PtL2a and PtL2c) with 4 molar equiv. of N-AcCys in D2O
were first monitored by 1H and 195Pt NMR spectroscopy. The reactions of the substitution-labile
precursors PtL1 and PtL2 were complete after 2 h, as shown by the appearance of a new signal in
the

195

Pt NMR spectra of both reactions. The signal due to starting material PtL1, at δ -2331.9,

was replaced by a signal at δ -2903.2, assigned to the reaction product [Pt(Mebpma)Cys]2+,
whereas the signal due to PtL2, at δ -2301.8, was replaced by that at δ -2848.3, also in agreement
with a square planar N3S coordination sphere, and therefore formation of [Pt(bpma)Cys]2+.35,36 The
195

Pt NMR spectra of both the PtL1 and PtL2 reaction mixtures after 24 h show that the intensity

of the signal assigned to the PtN3S complex has significantly decreased with the rise of broader
peaks in the same region suggesting that decomposition or further reaction in the presence of
excess N-AcCys had taken place. To examine this point further the time course of the reactions
were followed by 1H NMR spectroscopy.
The 1H NMR spectra of the two [PtCl(N3)]Cl compounds PtL1 and PtL2 show the same profile.
The spectral interpretation is complicated somewhat by the presence of excess N-AcCys but the
aromatic region is informative. The 1H NMR spectra of PtL1 and PtL2 in the aromatic region in
the presence of N-AcCys over 2, 6 and 24 h are presented in Figure 2.7. For PtL1 at 2 h, the
spectrum of the reaction mixture shows signals of coordinated Mebpma, which are shifted to
higher frequencies, δ 7.56 (t, 2H, H5), 7.66 (d, 2H, H3), 8.15 (t, 2H, H4), 9.11 (d, 2H, H6) in
comparison with those in both the free and coordinated Mebpma thus suggesting formation of the
product [Pt(Mebpma)Cys]+. The characteristic “pair” of doublets of the H7 protons is obscured
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somewhat by solvent but the downfield doublet diminishes in intensity and appears as a virtual
triplet (Figure 2.8). Over time a new set of signals arises with concomitant decrease of the initial
product peaks. The bulkier S-thiolate ligand could cause steric hindrance and the multiple signals
arising over time, along with the broadening of the PtNMR signals, could arise from the presence
of mixtures or isomers of [PtN3(Cys)]+. The related compound [PtCl(di-6-methyl-2picolyl)amine]+ (with a Me group in the C6 position of the N3 ligand , See Scheme 1) undergoes
relatively facile chelate ring opening in the presence of excess 9-EtGua to produce bisubstituted
bis(9-EtGua) products.37 Similar ring opening could be expected under the strong trans influence
of the thiolate ligand. The final product signals and an accompanying singlet at δ 4.31 are most
compatible with assignment to free ligand – the shifts are slightly different due to protonation in
the more acidic environment created by excess of N-AcCys (data not shown). The reaction of PtL2
occurs more quickly than for the Mebpma derivative. After 24 h the spectrum of the nonmethylated complex PtL2 reaction mixture presents signals assigned to only one aromatic species
and also attributed to free ligand (Figure 2.7).

Figure 2.7. 1H NMR (400 MHz) spectra in the aromatic region for reactivity assay of
PtL1 and PtL2 with N-AcCys. Hydrogens marked with a * are assigned to [Pt(N3)(NAcCys)]+ complex, and underscores assigned to the protonated free ligand.
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Figure 2.8. Complete 1H NMR spectra: reactivity assay of PtL1 and PtL2 with NAcCys.

Mass Spectrometry.
The ESI-MS spectra of 1:1 reactions are clean and consistent with the interpretation of the
initial NMR spectra. For PtL1 immediately upon incubation with one equivalent of N-AcCys (t =
0) the MS showed the major species of starting material (Figure 2.9B) whereas after 24 h this gives
way to a peak at m/z = 570.11 consistent with [Pt(Mebpma)(N-AcCys)]+ (Figure 2.9D). The
spectrum of PtL2 immediately upon incubation (Figure 2.9A) shows the presence of starting
material and also product [Pt(bpma)(N-AcCys)]+ with a very minor peak at m/z = 948.15
indicative of the μ-cysteine dimer [{Pt(bpma)2}μ-N-AcCys]+ (not shown). Thus, the MS data
confirm the greater reactivity of PtL2 over PtL1, as seen by NMR spectroscopy. After 24 h the
dominant peak is that of the mononuclear product (Figure 2.9C). An interesting feature at t = 24 h
is the presence of [{Pt(bpma)2}μ-N-AcCys]+ and a species at m/z = 1111.18 which corresponds to
[Pt(bpma)(N-AcCys)]2 (Figure 2.10). Isotopic distribution patterns of products were consistent
with these assignments in all spectra.
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The reactions of cysteine and glutathione (GSH) with Pt chelate complexes is usually discussed
in relation to the trans-labilization induced upon formation of the Pt-SR(thiolate) bond and also
the propensity to form bridged diplatinum μ-thiolate(SR) species.38,39 In the case of cisplatin,
binding of biologically relevant thiols such as cysteine and glutathione can result in rapid
dissociation of the Pt-NH3 bond.36,40 In the case of [PtCl(dien)]+ , dissociation of the dien ligand
eventually occurs over long periods of time upon reaction with both cysteine and glutathione.39
The results discussed here suggest that the bpma and Mebpma ligands are more susceptible to
ligand dissociation and trans labilization than the ‘aliphatic” dien ligand. The dinuclear
[{Pt(dien)}2μ-GS]3+ species has been observed in a rapid reaction of [Pt(dien)(GS)]+ with a second
[PtCl(dien)]+ unit.38 However, the peak assignable to formation of the μ-Cys dinuclear species for
PtL1 is of very minor intensity, suggesting that the increased “in-plane” steric demands of the
bpma and Mebpma ligands27 do not favor the approach of a second Pt unit to the first formed
[Pt(bpma/Mebpma)(N-AcCys)]+ species.
Gold Complexes.
The reactions of AuL1 and AuL2 with N-AcCys immediately produce white precipitates (data
not shown).

This behavior is identical to that observed for [AuCl(dien)]2+ and also

[Au(dien)(dmap)]3+.31 The thiol-containing amino acid L-cysteine quickly reduces Au3+ in
aqueous solution, the reaction being complete in the first minute.22,41,42 The initial rapid
substitution reaction results in an unstable Au(III)-S complex that is reduced to Au1+/Au0 in a
slower electron-transfer process.22,41
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Figure 2.9. MS spectra of 1:1 reaction between N-AcCys and (A) PtL2 immediately; (B)
PtL1 immediately; (C) PtL2 after 24 h; (D) PtL1 after 24 h.
r160606r01 #1-51 RT: 0.00-0.36 AV: 51 NL: 5.50E4
T: FTMS + p NSI Full ms [105.00-2000.00]
1111.1826

100

[Pt(bpma)(N-AcCys)]2

95
90
85

665.2468

80
75
912.0720
70

625.3160

Relative Abundance

65
60

1125.1884

55
50
734.0832

45

1020.1401
891.0983

40

948.1526

815.5981
35
30

793.3671

25
691.2627
20

762.0572

853.0973

15
10
1155.5083
1215.0668 1266.7179

5
1056.3861

1367.5895

0
600

650

700

750

800

850

900

950

1000
m/z

1050

1100

1150

1200

1250

1300

1350

1400

Figure 2.10. Expanded MS spectrum of 1:1 reaction between N-AcCys and
[PtCl(bpma)]Cl (PtL2) after 24 h.
68

Formally substitution-inert [Pt(N3)L] 2+ complexes.
In contrast with the results discussed above for the substitution-labile [PtCl(N3)]+ complexes
PtL1 and PtL2, the 1H and 195Pt NMR spectra obtained after mixing the [Pt(N3)L]Cl2 (PtL1a, PtL2a
and PtL2c) compounds with N-AcCys in 1:1 stoichiometric ratios do not show any change, even
after 72 h of incubation (Figure 2.11). When 1:4 {Pt:N-AcCys} stoichiometry is used in the
reaction of PtL1a, peaks of very low intensity appear after 24-72 h at δ = -2850-2900 ppm
indicating some formation of PtN3S species. These results confirm the inertness of the
[Pt(N3)L]Cl2 compounds in the presence of the sulfur-containing amino acid N-AcCys. In
principle, the advantage of a substitution-inert system, such as [Pt(N3)L]2+ complexes in general,
as an in vivo NCp7 inhibitors, is that they would not be easily “deactivated” by other sulfurcontaining biomolecules. In this context, efforts towards tuning these complexes is essential, so as
to favor reactions with strong nucleophiles, such as ZF cysteine residue thiol groups, as suggested
previously.19

Figure 2.11. 1H NMR spectra: reactivity assay of PtL1a with N-AcCys.
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Studies of the reactivity of complexes PtL1, AuL1 and PtL1a with the C-terminal finger of HIV
NCp7, ZF2.
The interactions between the [MCl(N3)]n+ (PtL1 and AuL1) and [Pt(N3)L]2+ (PtL1a) complexes
with the C-terminal finger of the HIC NCp7 peptide (ZF2) have been monitored by mass
spectrometry. Immediate interaction between PtL1 and ZF2 results in complete loss of the Zn2+
ion and Mebpma ligand (Figure 2.12A). The mass spectrum shows an intense peak at m/z of 371.50
assigned to the apoprotein [apoF]6+ and minor peaks at m/z of 445.40 [apoF]5+ and 556.49
[apoF]4+. The peak at m/z of 484.39 corresponding to [PtF]5+ proves that PtL1 was able to eject
the Zn2+ ion of the ZF2 domain, forming a 1:1 [Pt:F] adduct. To our knowledge this is the first
observation of the “simple” {PtF} species. After 24 h the spectra show adducts corresponding to
species with multiple Pt units [(PtL)-PtF]n+ perhaps from gas-phase interaction of PtL1 with the
initially pre-formed PtF (Figure 2.12B). The results contrast to those previously shown for
[PtCl(dien)]+ where the dien ligand is retained in the initial stages of the reaction producing species
such as Pt(dien)-ZF or Pt(dien)-F and no {PtF} species was observed.14,42 In contrast, the MS
spectrum obtained after incubation with [PtCl(dien)]Cl for 15 h (Figure 2.13), still shows the
presence of unoxidized ZF as the major product, at m/z of 762.31 (ZF3+) and 1144.46 (ZF2+), and
only a small peak corresponding to Pt(dien)-ZF3+ is observed at m/z of 862.33, which is very
similar to previous MS results for this complex.43 The results overall are broadly consistent with
the model NAcCys case discussed above. The greater reactivity of the Mebpma complex could be
related to its electron-withdrawing properties, due to the π-back bonding of the pyridine nitrogens,
responsible for its lesser basicity compared with dien.27 The same trend was observed previously
for the [MCl(dien)]n+ and [MCl(terpy)]n+ complexes.43
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Indeed, the behavior of {Pt(Mebpma)} species with total loss of ligand in the initial reaction
is more reminiscent of the general Au(III) behavior we observed here and previously.31,43 The MS
spectra of the AuL1 and ZF2 mixture indicate immediate reaction with peptide oxidation and
ejection of the Zn2+ ion (Figure 2.12C). As seen before for other gold(III) complexes,31,43 Zn2+
ejection and AuxFn+ formation occurs immediately, with peaks assigned to [Au2F]5+ (m/z =
523.78), [AuF]4+ (m/z = 604.98), [Au2F]4+ (m/z = 654.48), [AuF]3+ (m/z = 806.64), [Au2F]3+ (m/z
= 872.30) and [Au4F]3+ (m/z = 1003.61). Peaks corresponding to the oxidized apoprotein are also
seen at m/z of 445.00 [apoF5+], 555.99 [apoF4+] and 741.33 [apoF3+]. Careful examination of the
spectra show low intensity companion peaks of, for example, the apoF4+ species corresponding to
the presence of an extra 1, 2, or 3 oxygen atoms suggesting higher-order oxidized sulfur species
(Figure 2.14). The rapid reaction of AuL1 (and also [AuCl(dien)]2+) to form “gold fingers” is in
accordance with the greater reactivity of gold(III) compared with platinum(II) complexes.
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Figure 2.12. MS spectra of 1:1 reaction between NCp7 ZF2 of (A) PtL1 immediately; (B)
PtL1 after 24 h; (C) AuL1 immediately.
720

740

760

780

800
m/z

820

840

72

860

880

900

Figure 2.13. MS spectrum of the 1:1 mixture of [PtCl(dien)]Cl with
ZF2 after 15h.

Figure 2.14. Expanded version of ESI-MS spectrum of the product of
[Au(Mebpma)Cl]2+ and C-terminal ZF2 showing the apoF4+ ion and the
presence of associated oxidized -SO, -SO2 and -SO3 adducts of the
apopeptide.
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Substitution-inert [Pt(N3)L] 2+ Complexes.
For the incubation of the dmap-containing complex PtL1a with ZF2, which contains a fourth
nitrogen coordinated to the metallic ion, the mass spectrum (Figure 2.15) confirms the noncovalent interaction, as can be observed by the weak peaks assigned to the 1:1 adduct (PtL1a:ZF)
at m/z of 939.70 (PtL1a -ZF3+) (not shown), 1408.04 (PtL1a -ZF2+) and 1427.53 (K+ PtL1a-ZF2+).
It is noteworthy that even for a weak non-covalent interaction these peaks can be observed in the
ESI-MS spectrum under the appropriate conditions. No change is observed over time.

Figure 2.15. MS spectrum of the 1:1 mixture of [PtL1a]Cl2 with the C-terminal zinc finger
of HIV NCp7. The expansion of noncovalent adduct peak and the theoretical m/z are shown
in the right.
2.4 Conclusions
The reactions of {MClN3} species [PtCl(Mebpma)]Cl (PtL1) and [AuCl(Mebpma)](PF6)2
(AuL1) complexes and the analogous bpma complexes (PtL2 and AuL2) with N-AcCys and NCp7
ZF2 have been investigated. Comparison of the 1H NMR data suggest appreciable withdrawal of
electron density from the N3 ligand, which is more pronounced in the gold(III) complexes than in
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the platinum(II) analogues, and explains the facile deprotonation of AuL2 and the relative
instability of both gold(III) complexes, also associated with the ease of Au3+ reduction in both
cases.25 Indeed, only the platinum(II) N-heterocyclic compounds of the type [Pt(N3)L]Cl2 could be
isolated in their pure form from the reactions of the precursors PtL1 and PtL2 with 4dimethylaminopyridine (dmap), 9-ethylguanine (9-EtGua) and 4-methylpyridine (4-pic).
Formation of the analogous [Au(N3)L]3+ complexes occurs in solution and can be monitored by
1

H NMR Spectroscopy but no stable solid products were isolated.
As shown by the reactivity assay, the [Pt(N3)L]2+ complexes are inert and react only very

slowly with excess N-AcCys. In contrast, the [PtCl(N3)]+ complexes PtL1 and PtL2 react with NAcCys almost immediately to yield substitution products [Pt(N3)Cys]2+, which seem to undergo
decomposition with release of the chelate ligand after 24 h. The decomposition of the bpma
containing species is faster than that for Mebpma. These results are consistent with the ESI-MS
spectrometry results with the zinc finger which shows adducts M:F (apopeptide) adducts for PtL1
similar to that found for AuL1. For both complexes the reactions with ZF2 occur with Zn2+ ejection,
which is not seen for the [PtCl(dien)]+ analogue. The reaction with AuL1 occurs quickly, as seen
before for other gold(III) complexes, resulting in “gold fingers” and oxidized apoF peptide. These
results suggest a greater deactivation/inhibition action of the NCp7 ZF2 by the Mebpmacontaining complexes, especially for AuL1.
Interaction of the inert [Pt(N3)L]2+ complexes with Trp was investigated and the results show
that the presence of the dmap ligand results in complexes with considerable affinity for the amino
acid. Furthermore, PtL1a is one of the best Trp fluorescence quenchers among the complexes
reported herein and previously studied platinum(II) and gold(III) analogues both for the free
amino-acid and the NCp7 peptide sequence. The association constant determined with the full
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NCp7 peptide is significantly higher than that found for [Pt(dien)(9-EtGua)]2+ (Ka = 20 x 10-3 M-1
) and comparable to values found for organic inhibitors of the HIVNCp7-RNA interaction.44 The
association constant with the C-terminal finger is sufficiently strong that formation of the noncovalent PtL1a:ZF2 adduct may be confirmed by ESI-MS without Zn2+ ejection. In summary, it
was possible to improve the non-covalent π-π stacking interaction of [Pt(N3)L]2+ complexes with
Trp by tuning the ligands coordinated to the platinum(II) ion, with the potential for selective
interaction with the HIV-NCp7 protein.
The results are overall consistent with a greater reactivity of bpma over dien chelate. The
relative displacement of Cl- from [PtClN3]+ (where N3 = terpyridine, bpma and dien) by isosteric
pyridine nucleophiles has been discussed in terms of the reactivity and discrimination ability of
the {PtN3} reaction centre.26 The reactivity is linearly related to the basicity of the isosteric
entering nucleophiles and the ability of the substrates to discriminate among neutral nucleophiles
of different basicity was considered a measure of their relative electrophilicity terpy > bpma >
dien. Broadly, the results presented here and comparison with the previously studied
[PtCl(terpy)]+, 42 extrapolate these findings to biologically relevant thiols and thiol-containing
peptides. Indeed, bpma represents an intermediate case between terpy and dien. In this respect is
noteworthy that a peak at 311.0 m/z in the spectrum of AuL1 and the ZF2 may represent
{Zn(Mebpma)Cl}(Figure 2.12) with chelate transfer as observed previously with the terpy
analog.43 Both the electronic structure and steric demands in going from sp2 planar (terpy) to
sp2/sp3 (bpma) to all sp3 (dien) nitrogens may contribute to the kinetic differentiation as
suggested.25 Once again, these results indicate that it is possible to design new candidates to
interact more selectively with biomolecules. The inertia of the [Pt(N3)L]2+ complexes could be
useful in the search for more selective NCp7 inhibitors, once those complexes can react favorably
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with strong nucleophilic amino acids residues as ZF Cys residues, avoiding “deactivation”
reactions with other biomolecules (sulfur-containing Cys residues). The syntheses of novel
complexes containing different N-donor ligands that are able to form relatively stable complexes
with NCp7 or that lead to Zn2+ ejection are also under further investigation.
2.5 Experimental Section
Materials and methods.
[PtCl(dien)]Cl,29

[AuCl(dien)]Cl2,30

[AuCl(bpma)](OTf)2,25

and

bis(2-

pyridylmethyl)methylamine (Mebpma)45 were synthesized according to the literature. All reagents
used in this study were analytical grade and used without further purification. N-acetyltryptophan
(N-AcTrp),

N-acetylcysteine

(N-AcCys),

bis(2-pyridylmethyl)amine

(bpma),

4-

dimethylaminopyridine (dmap), 9-ethylguanine (9-EtGua) and 4-methylpyridine (4-pic), were
purchased from Sigma Aldrich. Apo-peptides were purchased from GenScript Corporation and
had the following sequences: NCp7 ZF2 (KGCWKCGKEGHQMKDCTER), and the full NCp7
(MQRGNFRNQRKNVKCFNCGKEGHTARNCRAPRKKGCWKCGKEGHQMKDCTERQAN
). The zinc finger peptides were prepared according to our published procedures 14,43 and
characterized by CD and mass spectrometry.
Synthesis.
[PtCl(Mebpma)]Cl (PtL1). cis-[PtCl2(DMSO)2] was stirred for 24 h in 20.0 mL of CH2Cl2 with
1.1 equiv. of Mebpma in the dark. The yellow solid was washed with CH2Cl2 and diethyl ether
and dried in vacuo (60% yield). Anal. Calcd. (%) for C13H15Cl2N3Pt(H2O)1.5: C, 30.84; H, 3.58;
N, 8.30. Found: C, 29.41; H, 3.13; N, 7.54. 1H NMR (D2O, 400 MHz): δ 3.05(s, 3H), 4.60 (d, J =
16.0 Hz, 2H), 5.17 (d, J = 12.0 Hz, 2H), 7,51 (t, J = 8.0 Hz, 2H), 7,65 (d, J = 8.0 Hz, 2H), 8.14 (t,

77

J = 8.0 and 4.0 Hz, 2H), 8.76 (d, J = 4.0 Hz, 2H). 195Pt NMR (85.80 MHz, D2O, δ/ppm): -2331.9.
IR (KBr, selected peaks)/cm–1: ν(PtCl) 377, ν(PtN) 441, 485.
[PtCl(bpma)]Cl (PtL2). Synthesized as described for PtL1, except for the use of 1.1 equiv. of
bpma. The suspension was filtered and the light grey solid, washed with CH2Cl2 and diethyl ether
and dried in vacuo (98% yield). Anal. Calcd. (%) for C12H13Cl2N3Pt: C, 30.98; H, 2.82; N, 9.03.
Found: C, 30.77; H, 2.57; N, 8.79. 1H NMR (D2O, 400 MHz): δ 4.65 (d, J = 16.0 Hz, 2H), 4.96
(d, J = 16.0 Hz, 2H), 7.21 (t, J = 8.0 Hz, 2H), 7.52 (d, J = 8 Hz, 2H), 7.98 (td, J = 8.0 and 4.0 Hz,
2H), 8.53 (d, J = 4.0 Hz, 2H). 195Pt NMR (85.80 MHz, D2O, δ/ppm): -2301.8. IR (KBr, selected
peaks)/cm–1: ν(PtCl) 322, ν(PtN) 449, 491.
[Pt(Mebpma)(dmap)]Cl2 (PtL1a). PtL1 was stirred in the dark under reflux for 5 h in 15.0 mL
of distilled water with 1 equiv. of dmap. The solution was stirred at room temperature for an
additional 19 h. The solvent was evaporated to near dryness and 20.0 mL of acetone were added
and the mixture, stirred for 30 min. The suspension was filtered and the brownish solid, washed
with acetone and diethyl ether and dried in vacuo (47% yield). Anal. Calcd. (%) for
C20H25Cl2N5Pt(H2O)5: C, 34.74; H, 5.10; N, 10.13. Found: 34.12; H, 4.84; N, 9.78. 1H NMR (D2O,
400 MHz): δ 3.06 (s, 3H), 3.15 (s, 6H), 4.66 (d, J = 16.0 Hz, 2H), 5.17 (d, J = 16.0 Hz, 2H), 6.84
(br s, 2H), 7.43 (t, J = 8.0 Hz, 2H), 7.73 (m, 4H), 8.18 (td, J = 8.0 and 4.0 Hz, 2H), 8.38 (br s, 2H).
195

Pt NMR (85.80 MHz, D2O, δ/ppm): -2413.1. IR (KBr, selected peaks)/cm–1: ν(PtN) 446, 489.
[Pt(bpma)(dmap)]Cl2 (PtL2a). Synthesized as described for PtL1a starting with PtL2, and

obtained as a white solid (87% yield). Anal. Calcd. (%) for C19H23Cl2N5Pt(H2O)5: C, 33.68; H,
4.91; N, 10.34. Found: C, 32.82; H, 4.77; N, 9.88. 1H NMR (D2O, 400 MHz): δ 3.15 (s, 6H),
overlapped (4H), 6.85 (br s, 2H), 7.37 (t, J = 8.0 Hz, 2H), 7.67 (m, 4H), 8.13 (td, J = 8.0 and 4.0
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Hz, 2H), 8.46 (br s, 2H).

195

Pt NMR (85.80 MHz, D2O, δ/ppm): -2401.5. IR (KBr, selected

peaks)/cm–1: ν(PtN) 450, 496, 526.
[Pt(bpma)(4-pic)]Cl2 (PtL2b). Synthesized as described for PtL2a except for the use of 1.15
equiv. of 4-pic, and obtained as a white solid (83% yield). Anal. Calcd. (%) for
C18H20Cl2N4Pt(H2O)2.5: C, 35.83; H, 4.18; N, 9.29. Found: C, 34.38; H, 3.74; N, 8.88. 1H NMR
(D2O, 400 MHz): δ 2.58 (s, 3H), overlapped (m, 4H), 7.35 (t, J = 8.0 Hz, 2H), 7.56 (d, J = 4.0 Hz,
2H), 7.67 (d, J = 8.0 Hz, 2H), 7.67 (br s, 2H), 8.15 (td, J = 8.0 and 4.0 Hz, 2H), 8.92 (br s, 2H).
195

Pt NMR (85.80 MHz, D2O, δ/ppm): -2405.5. IR (KBr, selected peaks)/cm–1: ν(PtN) 449, 494.
[Pt(bpma)(9-EtGua)]Cl2 (PtL2c). Synthesized as described for PtL2a except for the use of 1.15

equiv. of 9-EtGua and obtained as a light yellow solid (93% yield). Anal. Calcd. (%) for
C19H22Cl2N8OPt(H2O)3.5: C, 32.26; H, 4.13; N, 15.84. Found: C, 31.58; H, 4.10; N, 15.37. 1H
NMR (D2O, 400 MHz): δ 1.48 (syn) and 1.58 (anti) (t, J = 8.0 Hz, 3H), 4.22 (syn) and 4.31 (anti)
(q, J = 8.0 Hz, 2H), 4.95(m, 4H), 7.33 (q, J = 8.0 Hz, 2H), 7.57-7.66 (m, 4H), 8.12 (t, J = 8.0 Hz,
2H), 8.51 (syn) and 8.88 (anti) (s, 1H). 195Pt NMR (85.80 MHz, D2O, δ/ppm): -2362.7; -2379.0.
IR (KBr, selected peaks)/cm–1: ν(PtN) 447, 491.
[AuCl(Mebpma)](PF6)2 (AuL1) Synthesized analogously to [Au(bpma)Cl](PF6). To a stirring
solution of tetrachloroauric acid was added 1 equiv. of Mebpma in the presence of 2 equiv. of
ammonium hexafluorophosphate. The tan precipitate isolated by filtration and washed with water
(53.5% yield). Anal. Calcd (%) for [(C13H15N3)AuCl](PF6)2: C, 21.23; H, 2.06; N, 5.71. Found:
C, 21.29; H, 1.59; N, 5.93. 1H NMR (DMF-d7, 300 MHz): δ 3.94 (s, 3H), 5.47 (d, 2H), 6.35 (d,
2H), 8.13 (t, 2H), 8.31 (d, 2H), 8.72 (t, 2H), 9.13 (d, 2H).
[AuCl(bpma-H)](PF6) (Au(L2-H)) [Au(bpma-H)Cl](PF6) was synthesized by addition of 1
equiv. of BPMA to a solution of tetrachloroauric acid in water in the presence of 1 equiv. of
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ammonium hexafluorophosphate. The red precipitate was filtered and washed with water (70.7%
yield). Anal. Calcd. (%) for [Au(C12H12N3)Cl](PF6): C, 25.04; H, 2.10; N, 7.30. Found: C, 24.91;
H, 1.87; N, 7.14. 1H NMR (DMF-d7, 300 MHz): δ 4.40 (s, 4H), 7.96 (m, 2H), 8.21 (d, 2H), 8.55
(m, 2H), 9.14 (d, 2H).
NMR experiments.
1

1

H and

195

Pt NMR spectra were recorded on a Bruker AVANCE III 400 MHz spectrometer.

H NMR are reported with reference to solvent resonances of D2O at δ 4.79 – the dmf-d7 spectral

shifts were adjusted appropriately. The

195

Pt{1H} NMR spectra including those of the N-AcCys

assay were obtained in D2O, at room temperature, with 40 mM solutions, at an operating frequency
of 85.80 MHz, range of -1900 to -3500 ppm and 5000 scans. The spectra were referenced
externally using standards of Na2PtCl6 in D2O (δ = 0 ppm). The 1H NMR spectra of the 4-pic and
dmap platinum complexes were recorded on a Varian Mercury-300 MHz, at 293 and 333 K (60ºC).
The samples were prepared in D2O, at 20 mM approximate concentration and the spectra, obtained
with an average number of 32 scans.
Fluorescence spectroscopy.
Fluorescence studies were recorded on a Varian Cary Eclipse fluorometer. Solutions of the
[Pt(N3)L]Cl2 species were prepared in water to a final concentration of 1.5 mM. 1 mM stock
solutions of N-AcTrp, ZF2 and NCp7 were prepared in 20 mM tris buffer with 50 mM NaCl at pH
7.4. In a fluorescence cuvette, 3 mL of a 5 μM solution of N-AcTrp, ZF2 and NCp7 was titrated
with volumes of 10 μL of the stock solution of the platinum(II) compounds at molar ratios from 1
to 10, and the fluorescence emission was measured in a 300-450 nm range, with an excitation
wavelength of 280 nm and a detector voltage of 700 V for N-AcTrp and 750 V for ZF2 and NCp7
at room temperature. The emission maximum (360 nm) was measured after each titration. The Ka
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values were determined from Eadie-Hofstee plots and were determined from an average of 3 trials
using the following equation: ΔF = (Ka)−1ΔF/[quencher] + ΔFc.
Mass Spectrometry.
For the electrospray ionization mass spectrometry experiments, 1:1 mixtures of PtL1a:ZF2
was prepared. The samples were sprayed immediately using a final concentration of ~100 μM.
Experiments were carried out on an Orbitrap Velos from Thermo Electron Corporation operating
in positive mode. Samples were diluted with methanol and directly infused at a flow rate of 0.7
μL/min using a source voltage of 2.30 kV. The source temperature was maintained at 230°C
throughout. MCl(N3) complexes were incubated with N-AcCys or NCp7 ZF2 at 1: 1 molar ratios,
and the reaction mixtures at t = 0 and 24 hours were monitored by ESI-MS under the same
conditions.
Far infrared-(FIR) Spectroscopy.
Far Infrared (FIR) Fourier Spectra were obtained in KBr pellets in a Nicolet – Nexus 670 FTIR in the 600–200 cm-1 frequency range, with an average number of 32 scans.
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2.7 Appendix

Figure 2.16. Interaction of [Au(BPMA)Cl]+ with one equivalent of DMAP monitored by 1HNMR for 10 hours.

89

24 hrs
Bound
N(CH )

Possible N-(CH ) Shift

6 hrs

3 2

2 2

CH-π Interaction
30 mins
Bound DMAP

Bound DMAP

10 mins

Free DMAP

Free DMAP

0 mins
(CH)
4

N(CH3)2

Free DMAP
(CH)
8

N-(CH )
2 2

Free [Au(Me-BPMA)Cl]+

N-CH
3

Figure 2.17. Interaction of [Au(Me-BPMA)Cl]2+ with one equivalent of DMAP monitored
by 1H-NMR for 10 hours.
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3.1 Abstract
The HIV nucleocapsid protein NCp7 has been previously shown to play a number of roles in
the viral life cycle, and has previously been identified as a potential target for small molecule
intervention. In this work, the synthesis of the previously unreported complexes
[Au(dien)(1MeCyt)]3+, [Au(N-Medien)(1MeCyt)]3+, and [Au(dien)(Cyt)]3+ is detailed, and the
interactions of these complexes with models for NCp7 are described. The affinity for these
complexes with the target interaction site, the “essential” tryptophan of the C-terminal zinc finger
motif of NCp7, was investigated through the use of a fluorescence quenching assay and by 1HNMR spectroscopy. The association of [Au(dien)(1MeCyt)]3+ as determined through fluorescence
quenching is intermediate between the previously reported DMAP and 9-EtGua analogs, while the
associations of [Au(N-Medien)(1MeCyt)]3+ and [Au(dien)(Cyt)]3+ are lower than the previously
reported complexes. Additionally, NMR investigation of this interaction shows that the association
of complexes of this nature may be weaker than previously reported. The specifics of the
interaction with the C-terminal zinc finger were investigated by circular dichroism spectroscopy
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and electrospray-ionization mass spectrometry. The interaction is complete nearly immediately
upon mixing, and the formation of AuxFn+ (x = 1, 2, or 4; F = apopeptide) concomitant with the
loss of all ligands was observed. Additionally, for the first time oxidized dimerized peptide was
observed as a product, indicating reaction via a charge transfer mechanism.
3.2. Introduction
Gold compounds have a long history in medicinal chemistry. The thiophilic nature of gold
suggests sulfur-rich proteins such as thioredoxin as reasonable cellular targets for gold action.1
Au(III) is quite labile in its chemistry and susceptible to reduction to Au(I).1 Apart from the
inherent difficulty in understanding speciation of a Au(III) complex in a biological medium, nonselective interactions are also highly likely. This is especially true when highly nucleophilic sulfur
sites in proteins are considered as viable targets. Formally substitution-inert coordination spheres
such as MN4 or MN3L (where M = Pt, Au and N4 may be an N3 chelate such as diethylenetriamine
(dien) and L a purine or pyrimidine ligand) have been explored by our group for greater specificity
with biomolecules.2 In principle, we have suggested that highly nucleophilic cysteines of
biomolecules can be targeted using weak nucleophiles such as Platinum-Nucleobase PtN4
Complexes for selective peptide reactions. While Au(III) is chemically more reactive than Pt(II)
the same principle applies. A complementary approach to enhance selectivity in metal ionbiomolecule interactions is to use an inherent property of the protein along with appropriate design
of the small molecule. A two-stage approach to selectivity can then be envisaged – molecular
recognition followed by “fixation” where the inorganic moiety forms covalent linkages to the
protein of interest. In this contribution we summarize how this approach might work using
formally substitution-inert gold-metal nucleobase complexes and a tryptophan-containing zinc
finger peptide from the HIV nucleocapsid protein HIVNCp7. Specifically, we describe the
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synthesis and properties of Au(III)-1-MeCytosine complexes and their interactions with the Cterminal NCp7-F2 targeting the essential tryptophan of the protein.
Zinc binding proteins are one of the most common types of metalloprotein, and make up as
much as 10% of proteins found in humans.3 In these proteins, zinc can serve a catalytic role, a
structural role, and even a recently discovered inhibitory role.4,5 In zinc finger proteins, the zinc
serves a structural role binding in a tetrahedral geometry to four surrounding amino acids.6 These
amino acids are generally a combination of cysteines and histidines, and take the forms Cys2His2,
Cys2HisCys (Cys3His), or Cys4, and modification of the zinc-coordinating residues can have a
dramatic effect on protein function.7 The HIV nucleocapsid protein (NCp7), a 55 amino acid
protein that contains two Cys3His zinc fingers (Figure 3.1), has been identified as a potential target
for chemical intervention through the modification of these structural elements, and it has been
previously shown that alteration of the zinc coordination sphere significantly hinders viral
replication.4 NCp7 interacts with its polynucleotide substrate, viral RNA, through guanine stacking
with both W37 on the second C-terminal zinc finger motif, as well as through the phenylalanine
(F16) located on the first zinc finger.4,8
NCp7 recognition by small molecules can be optimized through a noncovalent π-π stacking
interaction between the “essential” tryptophan residue and metallated nucleobases, analogous to
the RNA(DNA) interaction. Previously reported gold (III) complexes based on [Au(dien)L]3+
(dien = diethylenetriamine; L = N-heterocycle) have been investigated for their ability to stabilize
the Au(III) oxidation state, as well as their ability to eject zinc from zinc finger proteins.9-12 In the
case of coordination complexes, this interaction brings the metal center in close contact with the
highly nucleophilic zinc bound cysteine residues, allowing for secondary electrophilic attack by
the metal center, resulting in zinc ejection.2,9 Changing the N-heterocyclic ligand can be used to
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fine-tune the electronic properties of the metal center to impart higher selectivity for the protein of
interest. To this end, the [Au(dien)L]3+ coordination sphere was studied with the previously
uninvestigated ligand 1-methylcytosine (1-MeCyt). Compared to the N-heterocycles 4Dimethylaminopyridine (DMAP) and 9-Etylguanine (9-EtGua), the free ligand 1-MeCyt has a
higher association constant with tryptophan.13 Additionally, 1-MeCyt has an intermediate basicity
(pKa = 4.45) relative to DMAP (pKa = 9.1) and 9-EtGua (pKa(N7) = 2.7).14 Previously, basicity of
the heterocycle was thought to be proportional to association constant in the [Au(dien)(Nheterocycle)]3+ motif.9 The [Au(dien)(1-MeCyt)]3+ is, to our knowledge, the first 1-MeCytosine
compound of Au(III) to be synthesized and completes the series of Pt(II) and Pd(II) complexes
[M(dien)L]n+ (L = 9-EtGua, 1-MeCyt) studied for their isostructural and isoelectronic
similarities.13,15,16 We report the synthesis of the [Au(dien)(1-MeCyt)]3+ (A), [Au(N-Medien)(1MeCyt)]3+ (B), and [Au(dien)(Cyt)]3+ (C) (Figure 3.1). The associative interaction with N-AcetylL-tryptophan (NAcTrp) as a model for the recognition site of NCp7 (W37) was probed through
the use of a fluorescence quenching assay. Additionally, the interactions with the C-terminal zinc
finger of NCp7 (Figure 3.1) were investigated by mass spectrometry and circular dichroism
spectroscopy.
3.3. Results
Synthesis and Characterization
The previously unreported complexes A, B, and C (Figure 3.1) were successfully synthesized
in accordance with the previously published methods.9 The 1H-NMR spectra of the complexes A
and of B show multiple protonation states with varying pH* (Figure 3.2), analogous to the
previously reported 9-EtGua analogs.9 As 1-MeCyt does not have a labile proton, the changes in
the shifts observed with changing pH may be due to the previously reported deprotonation of the
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dien chelate, likely at the central nitrogen (pKa = 3.3 for 9-EtGua analog).9 By analogy with the
Pd and Pt complexes (see reference 13), the N3 is assigned as the binding site to Au(III). Unique
to the 1-MeCyt complexes, the signals for the aromatic H6 protons split. This splitting of the
aromatic protons is not observed in the complex of C nor in the platinated analog, and highlights
the increased electronegativity of Au(III) relative to Pt(II).16,17

Figure 3.1. Structures of the complexes studied. Metal binding sites are highlighted in red.

Figure 3.2. The 1H-NMR spectra of A (left) and B (right) at varying pH* values, where pH*
is the reading of the pH meter.
The mass spectra of A and B are typical of many coordination complexes, in that the parent
ion peak is nearly indistinguishable from the background but the Au(III)-diethylenetriamine
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backbone bound to fragments of 1-MeCyt is observed, indicating that the desired product had been
obtained (Figure 3.3). Synthesis of the ribosylated analog of [Au(Dien)(Cyd)]3+ (Cyd = cytidine)
was attempted, but the recovered yellow product quickly turned purple, indicating the formation
of colloidal gold (reduction of the metal center to Au(0)).

Figure 3.3. Mass spectra of A (left) and B (right).
Determination of Tryptophan Affinity by Fluorescence Quenching
Complexes A, B, and C were titrated into a solution of NAcTrp, and fluorescence quenching
was used to determine the affinity (Figure 3.4). Complex B shows a lower affinity for NAcTrp (Ka
= 13.0 × 103 M-1) than the DMAP and 9-EtGua analogs. The association constant for A as
determined by tryptophan quenching (24.2 × 103 M-1) is intermediate between that of the DMAP
and 9-EtGua analogs, while C has a lower association constant (9.31 × 103 M-1). The synthesis and
study completes the isoelectronic and isostructural series [M(dien)L]n+ where M = Pd(II), Pt(II)
and Au(III) and L = purine, 9-Ethylguanine, or pyrimidine, 1-meCytosine.9,16 Figure 3.4 shows
how, for this closely related series, the electronic factors from individual metal ions can be
modulated to control to some extent the tryptophan affinity.13
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Figure 3.4. Association constants for [M(dien)(nucleobase)]n+ determined by fluorescence
quenching of NAcTrp.9,15,16
Interactions with Zinc Finger Proteins
Circular dichroism (CD) can be used to gain qualitative information about the structure of the
zinc finger protein. As previously described, the zinc finger structural motif, as seen in the second
finger of HIV-NCp7, has a characteristic positive band at 220 nm and a negative band at 195-200
nm.18 The CD spectrum of the C-terminal zinc finger motif of NCp7 (NCp7-F2) was recorded
before and after incubation with one equivalent of A, and the interaction was monitored for four
hours (Figure 3.5).
Similarly to all previously studied gold(III)-dien complexes, the interaction with A results in
rapid zinc ejection. The decrease seen in the positive band at 220 nm and the increase seen in the
negative band at 200 nm upon interaction are indicative of random coil, and are similar to the
previously reported CD spectrum of the apopeptide.10 Thus, it is assumed that the zinc has been
ejected very rapidly. Additionally, the spectrum does not change over the remainder of the next
four hours, indicating that the reaction is complete after 15 minutes. After a 15 minute incubation
with B, the result was also zinc ejection (data not shown).
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Figure 3.5. Circular dichroism spectrum of a 1:1 mixture of the C-terminal Zinc Finger of
NCp7 and A, monitored over 4 hours.
Mass spectra of a 1:1 mixture of NCp7-F2 and A were recorded immediately after mixing,
after 6 hours, and after 24 hours (Figure 3.6a, 3.7, and 3.8). The spectra did not change substantially
from the initial timepoint to the final measurement, supporting the results obtained in the CD
spectra and in the previous literature that the interaction between Au(III) complexes and zinc finger
peptides occurs rapidly. At the time of the initial measurement, the zinc-coordinated peptide is not
observed. Additionally, all Au-bound ligands are lost and only the well described “gold fingers”
are observed.10 Replacement of zinc by one, two, and four atoms of gold was observed: 605.4805
m/z (4+), 438.1595 m/z (6+), and 1003.2671 m/z (3+) respectively. This is the first instance that
incorporation of four gold atoms has been observed upon interaction with a single zinc finger
motif. Oxidized apopeptide (without zinc) is the most readily observable species; 741.3176 m/z
(3+), 1111.4739 m/z (2+). An unusual feature, not seen previously in our studies, is the presence
of oxidized dimerized apopeptide assigned to the mass observed at 889.5802 m/z for the n=5
charge state.
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(a)

(b)

Figure 3.6. Mass spectra of a 1:1 mixture of A (a) and B (b) with the C-terminal zinc finger of
NCp7.

Figure 3.7. Mass spectrum of A with NCp7-F2 immediately after mixing.
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Figure 3.8. Mass spectrum of A with NCp7-F2 6 hours after mixing.
Mass spectra of a 1:1 mixture of NCp7-F2 and B taken immediately upon mixing and after one
hour of incubation show essentially the same products as the spectra observed upon interaction
with A (Figure 3.6b, Figure 3.9). Additionally, there is little difference in the initial spectrum and
spectra obtained at later time points, again indicating that the reaction between NCp7-F2 and B is
very rapid. Oxidized peptide and oxidized dimerized peptide were again seen, as well as
incorporation of one, two, and four gold ions. Generally, because the ligands are not observed
attached to gold after interaction with zinc finger proteins, the species observed in the mass spectra
of the reaction with A and B are identical.

Figure 3.9. Mass spectrum of B with NCp7-F2 1 hour after mixing.
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Cyclic Voltammetry
CV studies of complexes A and B showed that the new complexes follow the trend of resistance
towards reduction seen in the previously studied DMAP and 9-EtGua analogs (Table 3.1).9 The
reduction potentials were determined relative to [AuCl(dien)]2+. The reduction potential of A is
intermediate between the previously studied DMAP and 9-EtGua analogs, and the Au(III)
oxidation state is stabilized relative to the AuClN3 coordination sphere. The reduction potential of
B is slightly higher than the previously studied DMAP analog, but is still slightly lower than the
chloride analog.
Complex

ΔEp (V)

Ref.

[Au(dien)(9-EtGua)]3+

-0.069

9

[Au(dien)(DMAP)]3+

-0.048

9

[Au(dien)(1-MeCyt)]3+ (A)

-0.052

[AuCl(N-Medien)]2+

+0.048

9

[Au(N-Medien)(9-EtGua)]3+

+0.017

9

[Au(N-Medien)(DMAP)]3+

+0.042

9

[Au(N-Medien)(1-MeCyt)]3+ (B)

+0.045

Table 3.1. Peak Potential Values (vs Ag/AgCl) for the reduction of selected Au(III)
complexes at a Platinum disc electrode relative to [AuCl(dien)]2+.
3.4 Discussion
The synthesis of complexes A and B serves to complete the series of complexes of the form
[M(dien)(1-MeCyt)]n+, in which the Pt(II) and Pd(II) complexes, which are both isoelectronic and
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isostructural to the Au(III) complexes investigated in this work, had been previously investigated,
but the Au(III) analog had remained unreported up to this point.
Tryptophan is present on the C-terminal zinc finger of NCp7, and plays an essential role in
protein-DNA/RNA recognition, which occurs through a π-π stacking interaction between the
aromatic tryptophan (or in the case of the full peptide, phenylalanine) residues and the nucleobases
in DNA/RNA.13,19 Previously, it has been shown that association with free N-Acetyl-L-tryptophan
(NAcTrp) is a good indicator of a compound’s affinity for the full protein. The fluorescent
emission of NAcTrp can be quenched by a complex that interacts with NAcTrp in a π-π stacking
interaction, and the degree to which the fluorescent emission is quenched is directly related to the
strength of the interaction.9-11,13,15,17
Compared to the Pt(II) and Pd(II) analogs, the Au(III) complexes show a higher affinity for
NAcTrp, consistent with the previous literature.4,20 The lower affinity of B for NAcTrp than the
DMAP and 9-EtGua analogs is surprising given the intermediate basicity of 1-MeCyt. The result
for A is as expected, as the basicity of free 1-MeCyt is intermediate between that of DMAP and 9EtGua, but the results obtained for B and C show that there are factors other than the basicity that
influence the associative interaction. Therefore, it is likely that the N-methyl group present on the
chelating ligand in B causes a lower association constant for the π-π stacking interaction with
NAcTrp than in A, shows that the modulation of the electronic environment of the metal center
can influence the interactions between the complex and the protein recognition element. However,
this reduction upon methylation of the chelating ligand is only observed to a lesser extent in the 9EtGua analog.
Mass spectrometry studies with the previously reported Au(III) analogs showed that the
formation of random coil observed by CD was accompanied by the formation of “gold fingers” in
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which one or more atoms of gold replaced the zinc in the zinc finger structure upon zinc ejection.9
The observation of oxidized apopeptide is indicative of disulfide bond formation between cysteine
molecules of the same peptide, while the observation of oxidized dimerized apopeptide is
indicative of disulfide bond formation between cysteine residues of different protein molecules.
These interactions would likely be facilitated by the reduction of the metal center from Au(III) to
Au(I)/Au(0). This interaction is in contrast to the interactions observed in the Pt(II) analogs, in
which reduction and incorporation of the Pt(II) metal center is not seen, and instead the metal
center is observed with the ligands intact and with the zinc still incorporated.4,17,20 As with the
previously reported aurated DMAP and 9-EtGua analogs, but unlike the platinated analogs, peaks
representing the unreacted zinc finger protein are not seen at the initial time point, highlighting the
increased reactivity of the Au(III) metal center. The incorporation of four equivalents of gold was
thought to be due to a difference in the redox properties of A and B when compared to the
previously studied Au(III) analogs. Therefore, cyclic voltammetry studies were carried out in order
to assess these differences.
Cyclic voltammetry showed that it is significantly easier to reduce cytosine and thymine than
it is to reduce adenine and guanine.21 In the context of interaction with zinc finger peptides, this
reduction would be accompanied by disulfide bond formation. In this case, the greater ease of
reduction may cause the occurrence of a charge transfer mechanism, in which the disulfide bond
formation occurs across two equivalents of the peptide forming the oxidized dimerized peptide
uniquely observed in the case of A and B, in contrast to the simple oxidation of one equivalent of
zinc finger. Whereas this latter oxidation is easily understood with reduction of Au(III) to Au(I)
and concomitant oxidation of two Zn-bound cysteines, the first step in peptide dimerization may
be an electron transfer between the 1-MeCyt ligand to the tryptophan ligand. This suggestion
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would explain why similar products would not be seen in the isostructural Pt(II) complexes, as the
platinum center is not reduced upon interaction with zinc finger peptides, while a charge transfer
mechanism must occur with concomitant reduction of the metal center.22 No evidence for selfassociation was observed by NMR studies for A or for free ligands (Figure 3.10). Previously
published work has discussed the reduction potential and accessibility of the cysteine residues of
the C-terminal zinc finger, and this data suggests that disulfide bond formation would likely occur
between C39 residues (Figure 3.11), as C39 has a reduction potential nearly as low as that of C49
(-33.35 vs. -35.91 mV), but has a much greater accessibility (52.88 vs. 15.17).22 It is also possible
that reduction of multiple molecules of A or B could also result in the formation of multiple
disulfide bonds, in which case both C49 and C39 could form disulfide bonds to form the dimer.

(a)

(c)

(b)

(d)

Figure 3.10. Self-association determination of (a) DMAP, (b) NAcTrp, (c) 9EtGua, and (d) A. In each case, self-association was negligible on the scale of
association between the complexes and NAcTrp.
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Figure 3.11. Illustration of disulfide bond formation. Zinc coordinating residues are
highlighted in red.

3.5. Materials and Methods
[AuCl(dien)]Cl2 and [AuCl(N-Medien)]Cl2 were synthesized according to previously
published procedures.23 1-Methylcytosine was synthesized and purified according to previously
published procedures.24,25 Addition of the N-heterocycles were carried out analogously to
previously published procedures.9 All NMR studies were carried out in deuterium oxide on a
Bruker AVANCE III (400 MHz). CD studies were carried out at 50 µM concentrations in water
on a Jasco J-1500 spectrometer. Mass spectrometry studies were carried out on a Thermo Electron
Corporation Orbitrap Velos mass spectrometer. Mass spectrometry samples were prepared at 10
µM concentrations in 10% methanol, and were sprayed at 2.30 kV and 0.9 µL/minute at 230 °C.
Synthesis of [Au(dien)(1-Mecyt)](NO3)3 (A): [AuCl(dien)]Cl2 (101.2 mg, 0.249 mmol) was
dissolved in dH2O (10 mL). 1-Methylcytosine (30.2 mg, 0.242 mmol) and Silver nitrate (125.4
mg, 0.738 mmol) were added, and the reaction mixture was stirred under light protection for 72
hours. The precipitated silver chloride was removed by filtration through celite, and the filtrate
was evaporated to dryness under reduced pressure. The orange/yellow residue was dissolved in a
small amount of dH2O, and acetone was added to the cloud point. The orange/yellow solid product
was collected by vacuum filtration, and characterized by 1H-NMR, Infrared spectroscopy, and
elemental analysis (experimental(theoretical)): C: 14.46% (14.62%) H: 2.81% (2.86%) N: 17.70%
(17.17%). 1H NMR (D2O, 400 MHz): 7.83 (d, 0.35H), 7.73 (d, 0.65H), 6.14 (d, 1H), 3.69 (broad,
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5.9), 3.45 (s, 3H), 3.18 (broad, 2.1H). UV-Vis (1 mM, H2O): 237 nm (Abs = 3.98), 357 nm (Abs
= 0.408).
Synthesis of [Au(N-Medien)(1-MeCyt)](NO3)3 (B): [AuCl(N-MeDien)]Cl2 (100.12 mg, 0.238
mmol) was dissolved in dH2O (10 mL). Silver nitrate (121.4 mg, 0.715 mmol) and 1methylcytosine (29.8 mg, 0.238 mmol) were added and the reaction mixture was stirred under light
protection for 4 days. The reaction mixture was filtered through celite and the solvent was
evaporated under reduced pressure. The resulting crude product was dissolved in a small amount
of water and excess acetone was added to precipitate the yellow product, characterized by 1HNMR, Far-IR, and elemental analysis (experimental(theoretical)): C: 16.77%(17.20%) H:
3.33%(3.46%) N: 17.69%(18.05%). 1H NMR (D2O, 400 MHz): 7.82 (d,0.66H), 7.72 (d, 0.38H),
6.13(d, 1H), 4.21 (d, 1.6H), 4.09 (m, 2.6H), 3.65 (m, 2.6H), 3.46 (d, 1.8H), 3.38 (s, 3H), 3.19 (m,
2.4H). UV-VIS (1 mM, H2O): 237 nm (Abs = 3.94), 352 nm (Abs = 0.921).
Synthesis of [Au(dien)(Cyt)](NO3)3 (C): [AuCl(dien)]Cl2 (100.44 mg, 0.168 mmol) was
dissolved in dH2O (10 mL). Cytosine (28.2 mg, 0.164 mmol) and Silver nitrate (85.61 mg, 0.506
mmol) were added, and the reaction mixture was stirred under light protection overnight. The
precipitated silver chloride was removed by filtration through celite, and the filtrate was
evaporated to dryness under reduced pressure. The orange residue was dissolved in a small amount
of dH2O, and acetone was added to the cloud point. The orange solid product was collected by
vacuum filtration. 1H NMR (D2O, 400 MHz): 7.64 (d, 1H), 6.06 (d, 1H), 3.52 (t, 4H), 2.99 (broad,
4H).
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Fluorescence Quenching of Tryptophan
Tryptophan quenching methods were adapted from those previously published.9 A solution of
N-acetyl-L-tryptophan (5 µM) was titrated with the Au(III) complexes (7.5 mM) in amounts
ranging from 1-10 equivalents of quencher.
Determination of Self-Association by NMR Spectroscopy
Varying concentrations (0.1-2.5 mM) of N-heterocycle and gold(III) complex were analyzed
by 1H-NMR. The degree of self-association was determined by previously published methods.26
Microsoft Excel Solver was used to solve the three variable equation.
Determination of Tryptophan Association by NMR Spectroscopy
The association between NAcTrp and π-π stacking compounds was determined through the
use of a Benesi-Hildebrand plot, adapted from the previously published method.19
Cyclic Voltammetry
Cyclic voltammetry studies were carried out following the previously published procedures. 9
A three-electrode cell was employed, containing a platinum disk working electrode, a platinum
mesh counter electrode, and a silver/silver chloride reference electrode (0.1 M KCl). Solutions
were degassed with nitrogen for 15 minutes before analysis. Measurements were obtained in 50
mM phosphate buffer (4 mM NaCl, pH = 7.4).
3.6 Conclusions
In conclusion, the previously unreported 1-methylcytosine complexes based on the
[Au(dien)(N-heterocycle)]3+ motif, A and B, have been synthesized and investigated for their
ability to interact with the C-terminal finger of the HIV nucleocapsid protein NCp7 as a model for
a protein with highly nucleophilic cysteines. Gold compounds are considered to primarily interfere
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with protein, rather than DNA, function. In considering the series [M(dien)L]n+ the electronic
properties can be modulated systematically for optimal protein interaction. A key feature leading
to the rational design of complexes of the form [Au(dien)L]3+ is the enhancement of the redox
stability of the complexes relative to the precursor [AuCl(dien)]2+ due to the incorporation of a
more substitution inert nitrogen donor in the form of an N-heterocycle.9 In the case of the more
sterically hindered complex B, the reduction potential is greater than the chloride analog [AuCl(NMedien)]2+, and is in line with the reduction in stabilization of the gold(III) oxidation state seen in
the complex [Au(N-Medien)(DMAP)]3+.

Secondly, the aurated nucleobase may interact

preferentially with an RNA(DNA) recognition motif such as tryptophan. Formation of oxidized
dimerized peptide was observed in the mass spectrometry studies conducted with NCp7-F2 and
indicated a difference in the reactivity profile of A and B compared to the previously studied
DMAP and 9-EtGua analogs. These results further confirm that by tuning the electronic and steric
properties of the ligands on the Au(III) coordination sphere, the strength of interaction between
complexes of the [Au(dien)(N-heterocycle)]3+ motif and a zinc finger can be modulated in a
systematic manner.
Funding: This research was funded by National Science Foundation.
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3.8 Appendix
NMR Association Studies
The inner filter effect is a concern in studies of the association of complexes of the [Au(dien)(Nheterocycle)]3+ structure, as there is some overlap in the absorbance spectrum of the gold(III)
complexes with the fluorescent absorption/emission spectra of N-acetyltryptophan. This overlap
would artificially inflate the association value determined for a complex with N-acetyltryptophan,
as the incident photons or emitted photons may be absorbed by the free gold(III) complex in
solution. In order to address this issue, NMR experiments were carried out in order to investigate
the potential of NMR as a method of determining the association between the gold(III) complexes
and N-acetyltryptophan. In order to prove this concept, the free N-heterocycle DMAP was first
investigated, as it is easily purchased at a low cost. However, DMAP has a fluorescence emission
of its own, meaning the data previously obtained for association of DMAP with Nacetyltryptophan by fluorescence quenching may also be artificially higher than expected. In order
to confirm that the data obtained from the NMR determination of association constant was valid,
the free N-heterocycle 9-Ethylguanine was also investigated, as the free 9-ethylguanine does not
have any spectral overlap with the N-acetyltryptophan. Finally, A was investigated in order to
determine the difference in show that this method can be applied to a gold(III) complex. In order
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to confirm that the system was a simple equilibrium system, and not a system in which a preassociation was present, the ability of the complexes to self-associate was also investigated by 1HNMR. The self-association of the complexes was determined using the equation 𝛿𝑜𝑏𝑠 = {[−𝐾𝑑 +
(𝐾𝑑2 + 8𝐶𝐾𝑑 )1⁄2 ]/4𝐶}(𝛿𝑀 − 𝛿𝐷 ) + 𝛿𝐷 , where 𝛿𝑜𝑏𝑠 is the observed, or average, chemical shift, 𝛿𝑀
is the chemical shift of the monomer, 𝛿𝐷 is the chemical shift of the dimer, and C is the total
concentration of the molecule. On the scale of the associations with N-acetyltryptophan, any preassociation was determined to be negligible.
In addition, the binding stoichiometry of free DMAP and [Au(dien)(DMAP)] 3+ with NAcTrp
were investigated by Job’s method as previously described.27 The final total concentration was 2.5
mM.
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Figure 3.12. 1H-NMR determination of the association between DMAP and Nacetyltryptophan.
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Figure 3.13. 1H-NMR determination of the association between 9-EtGua and Nacetyltryptophan.
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Figure 3.14. 1H-NMR determination of the association between A and N-acetyltryptophan.
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Complex

Ka (× 103 M-1)

DMAP

0.236

9-EtGua

1.54

[Au(dien)(1-MeCyt)]3+ (A)

2.68

Table 3.2. Association constants with N-acetyltryptophan as determined by BenesiHildebrand treatment of 1H NMR data.
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Figure 3.15. 1H-NMR determination of the self-association of DMAP.
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Figure 3.16. 1H-NMR determination of the self-association of N-acetyltryptophan.

Figure 3.17. 1H-NMR determination of the self-association of 9-ethylguanine.
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Table 3.3. Determination of the self-association of DMAP.
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Table 3.4. Determination of the self-association of N-acetyltryptophan.
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Figure 3.18. 1H-NMR Job’s Plot of the interaction between free DMAP and NAcTrp.
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Figure 3.19. 1H-NMR Job’s Plot of the interaction between [Au(dien)(DMAP)]3+ and
NAcTrp.
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Chapter 4: Synthesis, Crystal Structure, and Protein
Interactions of a Triphenylphosphine Au(C^N)
Complex – Carbon-Sulfur Transfer Mechanisms on
HIV NCp7
James F. Beaton, Douglas H. Nakahata, Faik Musayev, Martin K. Safo, and Nicholas P. Farrell
4.1 Abstract
The synthesis, characterization, and crystal structure of the previously unreported complex
[AuCl(dampa)(PPh3)]1+ are detailed. The interactions of this complex, and of the previously
reported AuCl2(dampa), with NCp7 and smaller models show the possibility for gold-mediated
transfer of the dampa and triphenylphosphine ligands to the sulfur of the protein and models. These
interactions provide a novel method of targeting zinc finger proteins.
4.2 Introduction
The HIV Nucleocapsid Protein (NCp7) is involved in many critical processes in the viral life
cycle, and is an example of a zinc finger protein.1,2 NCp7 has two tetrahedrally coordinated zinc
atoms, also known as zinc fingers, and modification or deletion of the zinc coordinating residues
causes loss of protein function.3,4 This loss of function has a strong negative impact on the efficacy
of the virus.4 Selective targeting of zinc finger proteins is a problem that has been widely discussed
across the literature, but in many cases there are still significant challenges that must be addressed.
The use of coordination complexes has been employed to obtain reactivity profiles that are
unavailable through the use of organic molecules, including the leveraging of molecular
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geometries and unique electronic properties to gain access to mechanisms of interaction beyond
the use of an oxidation/reduction mechanism directly attacking the zinc coordinating residues. For
example, the use of an N-heterocyclic ligand bound to a metal center such as Pt(II), Pd(II), or
Au(III) allows for a π-π stacking with the tryptophan and phenylalanine residues.5–14 This stacking
interaction allows for a much weaker electrophile to attack the neighboring cysteine residues due
to the proximity between the electrophile and the zinc coordinating residues. In the case of these
complexes, it was shown that the use of a metal center enhanced the π-π stacking ability of the Nheterocyclic ligands to a greater extent than organic modification, highlighting the advantages of
the use of coordination complexes in addressing complex challenges such as the selective targeting
of zinc finger proteins.
Reaction mechanisms other than π-π stacking followed by electrophilic attack can also be
achieved through the use of coordination complexes. Additionally, the “soft” nature of gold also
suggests that it should interact readily with sulfur containing biomolecules, and indeed this
phenomenon is borne out in the literature.15,16 Most of the previous studies carried out between
zinc finger proteins and gold-containing coordination complexes show that the major product is
the replacement of the zinc ion with one or more gold atoms, referred to as the formation of “gold
fingers”.10 Recently, however, Au(III) complexes containing a gold-carbon bond have been shown
to have the ability to covalently modify polypeptides by transferring the C-donating ligand to a
sulfur containing residue such as cysteine.17,18 This work was expanded to zinc finger proteins in
the case of the complex Au(bnpy)Cl2 (bnpy = benzylpyridine), and it was shown that this covalent
modification of the protein was possible by transfer of the benzylpyridine ligand to cysteine. This
transfer is thought to occur by a ligand replacement, in which the cysteine replaces a gold bound
chloride, followed by reductive elimination at the metal center, resulting in the covalent
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modification of the zinc-coordinating residue.19 By leveraging the unique ability of Au(III) to
undergo this reaction, and by making use of the observation that altering the Au(III) coordination
sphere gives the ability to tune the reactivity of the complex, may lead to the development of a
Au(III) complex with a favorable reactivity profile that is selective for NCp7.
4.3 Results and Discussion
The structures of the complexes studied are shown in figure 4.1. The crystal structure of A has
been previously reported.20 Compound B crystallized in a monoclinic crystal system, Cc space
group. The crystal structure is shown in figure 4.2. The asymetric unit confirms the formation of
the Au-C^N chelate and the coordination of triphenylphosphine trans to the Au-N bond. The
charge balance is achieved by the presence of hexafluorophosphate as a counterion, and
chloroform molecule of crystallization was present. This configuration is contradictory to the
expected geometry were the complex to follow the traditional trans-effect order of ligands.
However, it is not the first time that a complex has defied the trans-effect when forming, and the
phenomenon has previously referred to as “transphobia”, in which a destabilizing effect is
observed when two soft ligands are trans to one another. Other complexes with the dampa ligand
also exemplify this effect, so that substituents containing donor atoms of high trans influence, such
as S and C, are always located trans to the N rather than the C.21–25 The gold atom deviates from
planarity (as determined based on the four coordinating atoms) by 0.079 Å (r.m.s.), with a τ4
parameter of 0.13.26 The –CH2– group of the dampa ligand is located 0.466 Å away from the plane
defined by N1–Au1–C1–C6, which may explain the observed splitting of the protons in the NMR
spectrum.
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A

B

Figure 4.1. The structure of complex A (top left), B (top right), and NCp7 (bottom).

The main bond lengths and angles for B are listed in Table 4.1. The Au-N bond length was
2.141 Å, which consistent with the average for previously reported complexes of with similar C^N
chelating systems of 2.12(7) Å. The Au-C bond length of 2.049 Å is shorter than the Au-N
distance, and is also consistent with the average for previously reported complexes of 2.03(4) Å.
This is consistent with the strong σ-donor character of the deprotonated phenyl ring. The Au-P
bond length is the longest of the gold-coordinated ligands at 2.300 Å, but this is also consistent
with the average Au-P bond length for reported Au(III) complexes of 2.30(2) Å. The crystal
packing is stabilized by non-classical hydrogen bonding between the dampa CH2 and the fluorine
of hexafluorophosphate. This interaction is also present between the benzene hydrogen atoms and
both the fluorine of hexafluorophosphate and chlorine of chloroform. The supramolecular structure
of B is mainly formed by non-classical hydrogen bonding between the gold complex,
hexafluorophosphate, and chloroform (see Appendix).
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Figure 4.2. Molecular view of compound B. Displacement ellipsoids are drawn at the 50%
probability level. The chloroform molecule was omitted for clarity.
Au1–C1

2.049 (13)

C1–Au1–N1

82.1 (5)

Au1–N1

2.141 (10)

P1–Au1–Cl1

91.15 (11)

Au1–P1

2.300 (3)

N1–Au1–Cl1

91.1 (3)

Au1–Cl1

2.360 (4)

C1–Au1–P1

95.5 (4)

Table 4.1. Selected bond lengths (Å) and bond angles (°) of the crystal structure of B.
In order to investigate the potential for A and B to target cysteine, the reaction between NAcetyl-L-Cysteine (NAcCys) was studied by NMR spectroscopy (Figure 4.3) and mass
spectrometry (Figure 4.6). Immediately upon mixing a 1:1 solution of A or B with NAcCys, the
1

H-NMR signals for the chelate aromatic protons and the NAcCys protons show that a reaction is

underway. After 12 hours of time has elapsed, the signals have resolved, indicating that the reaction
is complete and that a new product had formed. Additionally, in the NMR spectra of A and B the
chelate –CH2- peak is resolved into a singlet. This is in contrast to the analogous AuCl2(bnpy), in
which the rigid steric constraints imposed by the pyridine moiety cause splitting of the –CH2-
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protons.19 This phenomenon was also previously observed in the complex [Au(BPMA)Cl]2+
(BPMA = di-2-(picolyl)amine), and shows that there is the potential for modulation of the steric
properties of the chelate, which could be leveraged to investigate new structure-activity
relationships in order to effectively target NCp7.27 However, this makes the NMR spectrum of the
reaction product somewhat more difficult to interpret, as the resolution of the split peaks into a
singlet was used to confirm C-S transfer in the case of Au(bnpy)Cl2.19

Figure 4.3. Interaction of A with NAcCys at time of mixing and 12 hours.
In order to determine the identity of the product that formed, a 1:1 mixture of A and NAcCys
was examined by mass spectrometry. After 24 hours, signals representative of [dampa-AuNAcCys] (m/z = 493.0801, 1+) and the carbon-sulfur transfer product [dampa-NAcCys] (m/z =
297.1237, 1+) are observed, confirming that the product observed by NMR is the result of a C-S
transfer process. A 1:1 mixture of B and NAcCys showed presence of similar products, however
in some cases two equivalents of dampa were observed bound to cysteine (m/z = 423.2828, 1+).
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Figure 4.4. Interaction of B with NAcCys at time of mixing (bottom), 6 hours (middle), and
24 hours (top).

Similar studies were carried out using glutathione (GSH) to investigate the ability of A and B
to interact with a larger sulfur containing biomolecule. As in the case of NAcCys, NMR
spectroscopy shows that a distinct product has formed after 12 hours of reaction time (Figure 4.4).
Similarly to the reaction with NAcCys, the mass spectrum of a 1:1 mixture of A and GSH showed
formation of both the gold-bridged intermediate dampa-Au-GSH (m/z = 637.1356, 1+) and the CS transfer product dampa-GSH (m/z = 441.1782, 1+) (Figure 3). Additionally, a signal representing
[Au(dampa)]2-GSH was observed (m/z = 966.1831, 1+). After 24 hours, the signals for all three
products were still present, indicating that the reaction was incomplete or that it is possible for the
final product to contain a bridging gold atom. Unlike the previously investigated Au(bnpy)Cl2, the
C-S transfer product was observed and the signal for oxidized glutathione (GSSG+, m/z = 613.15)
was not observed, indicating that reduction of the metal center is coupled to the C-S transfer
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process in the case of A.19 Mass spectrometric analysis of a reaction of B and GSH showed that
identical products formed despite the presence of the triphenylphosphine ligand (Figure 4.7).

Figure 4.5. Interaction of B with NAcCys at time of mixing and 24 hours.
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Figure 4.6. Interactions of A with NAcCys (left) and GSH (right).
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Figure 4.7. Mass spectrum of the product of the interaction of B with GSH after 24 hours.
The triphenylphosphine ligand on B also allows for the use of 31P-NMR as a tool for elucidating
the nature of the product formed. The chemical shift of the triphenylphosphine ligand on B appears
at 36.94 ppm (relative to trimethylphosphate). This is a significant downfield shift with respect to
previously reported Au(I) complexes, which appear at roughly 30 ppm.28 The interactions of B
with NAcCys and GSH are shown in figures 4.8 and 4.9 respectively. The
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P-NMR studies

conducted confirm that a reaction occurs between B and the sulfur containing molecules. After 24
hours of incubation time with NAcCys, an upfield shift is observed. The final product has a
chemical shift of 32.13 ppm. The upfield shift observed in this case is in contrast to the product
observed when Au(I) complexes are incubated with NAcCys, which produces a downfield shift
and a final chemical shift of roughly 39 ppm. Instead, the final product has a chemical shift closer
to the chemical shift of the previously studied Au(I) complexes, supporting the proposed reductive
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elimination mechanism of C-S transfer, which would produce a triphenylphosphine containing
Au(I) complex as a product.28

Figure 4.8. Interaction of B (bottom) with NAcCys after 24 hours (top) monitored by 31PNMR.

After 24 hours of incubation with GSH, two product peaks are observed, both of which are
shifted upfield from B. The larger of the two has a chemical shift of 31.27 ppm and is likely the
Au(I) reductive elimination product as seen in the reaction with NAcCys. The second smaller peak
has a chemical shift of 23.17 ppm and may be representative of the intermediate in which the C-S
transfer is not complete, indicating that the reaction is slower in the case of the more sterically
hindered GSH. However, it is also possible that this peak is the result of the previously reported
“ligand scrambling” effect observed in the case of phosphine-containing Au(I) complexes, but this
is unlikely, as ligand scrambling has been reported to cause a downfield shift rather than an upfield
shift.28
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Figure 4.9. Interaction of B (bottom) with GSH after 24 hours (top) monitored by 31P-NMR.
Upon interaction with the full NCp7 protein, a variety of products were identified by mass
spectrometry (Figure 4.10). Immediately after mixing a solution of NCp7 with one equivalent of
A per zinc finger, the presence of signals corresponding to both the gold bridged product, Peptide(Au(dampa))2 (m/z = 850.9478 (7+), 744.8303 (8+), 662.0722 (9+)), and the C-S transfer product,
Peptide-(dampa)2 (m/z = 617.2978 (9+), 556.5256 (10+)), were observed (where peptide is NCp7
in which the two coordinated zincs have been lost). The C-S transfer signals were present at a
significantly lower abundance at this timepoint. Other signals that were identified include the
formation of gold fingers with 2 (m/z = 677.1949 (8+), 609.6763 (9+)) and 5 (m/z = 909.3537 (8+),
808.5375 (9+)) equivalents of gold per finger were observed. Signals corresponding to [PeptideAu7-dampa2] (m/z = 992.1113 (7+), 868.2231 (8+), 771.8650 (9+), 694.8798 (10+)) may be
representative of an intermediate in which a gold finger containing 5 gold atoms is formed in place
of one zinc finger, and gold bridged cysteines are present on the other finger. Signals
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corresponding to [Peptide+Au+dampa] (m/z = 937.9295 (6+), 804.0841 (7+), 703.6997 (8+),
625.6223 (9+), 563.1609 (10+)) were also present in high abundance at the initial timepoint, which
likely represent a peptide sequence in which one of the fingers has become a gold finger, and the
other has complexed dampa through a C-S transfer reaction. This binding motif is more probable
than a gold-bridged motif in this case, as both zinc atoms are lost. Interestingly, at the initial
timepoint, signals representing [Peptide-(Au(dampa)Cl)2] were observed (669.1698 (9+),
1002.5328 (6+)). This further shows that incorporation of the Au-C bond significantly slows the
reaction between the gold complex and the protein, as in most previous examples chloride is not
observed bound to gold at even the earliest timepoints.

Figure 4.10. Interaction of A with NCp7 immediately after mixing.
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Product Identity
Peptide + Au + dampa

Theoretical m/z
703.718+
625.639+
563.1710+
850.957+
744.718+
662.089+
992.087+
771.849+
694.7610+
909.428+
808.499+

Peptide + 2(Au) + 2(dampa)

Peptide + 7(Au) + 2(dampa)

Peptide + 10(Au)

Observed m/z
703.708+
625.629+
563.1610+
850.957+
744.838+
662.079+
992.117+
771.879+
694.8810+
909.358+
808.549+

Table 4.2. Products of the reaction between A and NCp7 identified by mass
spectrometry immediately after mixing.

After 24 hours of incubation with A (Figure 4.11), the most readily observable signals were
those of [peptide-Au4-(dampa)2] (m/z = 1057.9220 (6+), 907.0779 (7+), 793.8193 (8+), 705.7289
(9+)). In this case, it is possible that the two equivalents of dampa are bridged by gold in the form
[peptide-{Au(dampa)}2-Au2] in which dampa is still gold bridged, but it is also possible that all of
the gold atoms and dampa ligands are bound to the peptide separately. The second most prominent
set of signals present after 24 hours is that of the form [Peptide-Au2-(dampa)2-Cl2] (m/z =
1002.0646 (6+), 858.9129 (7+), 751.9252 (8+), 669.1960 (9+), 602.3768 (10+)). The presence of
these signals after 24 hours indicates that the gold bound to chloride state is significantly longer
lived than in the previously studied AuN4 complexes, in which gold bound to chloride was not
observed after any significant length of time. In fact, even in the analogous complex Au(bnpy)Cl2
(another complex with an Au-C bond), gold bound chloride was not observed19. Other signals
observed after 24 hours of incubation include [Peptide-(dampa)2] (m/z = 617.5116 (9+), 555.9616
(10+)), which is also observed at the initial timepoint, and signals representing the peptide with
two gold fingers with two gold atoms each, [Peptide-Au4] (m/z = 760.5781 (8+), 676.1805 (9+),
608.6635 (10+)), and peptide with two gold fingers with five gold atoms each, [Peptide-Au10] (m/z
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= 1039.1155 (7+), 909.4774 (8+), 808.5365 (9+)). The formation of gold fingers is analogous to
the reactivity profile seen in the previously investigated gold(III) complexes possessing an AuN 4
coordination sphere, and shows that although a different product, in the form of the C-S transfer
product, is obtainable through the use of the Au-C containing complex, mechanisms similar to the
previously observed are still possible10. In the case of A, it is likely that the two labile Au-Cl bonds
are responsible for the formation of gold finger products, as even at the initial timepoint the
formation of the gold finger motifs were observed (ex. [Peptide-Au7-(dampa)2]).

Figure 4.11. Interactions of A (left) and B (right) with NCp7 after 24 hours. Product
configurations shown in the figure legends but not seen in the spectrum are shown in the
tables.
Product Identity
Peptide + 4(Au) + 2(dampa)

Theoretical m/z
1057.936+
906.947+
793.708+
705.629+
1002.086+
859.077+
669.179+
602.3610+
617.529+
555.9710+
808.499+
608.6510+
677.179+
760.308+

Peptide + 2(Au) + 2(dampa) + 2(Cl)

Peptide + 2(dampa)
Peptide + 10(Au)
Peptide + 4(Au)

Observed m/z
1057.926+
907.087+
793.828+
705.739+
1002.066+
858.917+
669.209+
602.3810+
617.519+
555.9610+
808.549+
608.6610+
677.199+
760.298+

Table 4.3. Products of the reaction between A and NCp7 identified by mass
spectrometry 24 hours after mixing.
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Identity
Peptide + 2(PPh3) + 4(Au)

Theoretical m/z
944.097+
826.218+
Peptide + 2(PPh3) + 3(Au)
916.107+
801.718+
712.749+
Peptide + 3(dampa) + 3(PPh3) + 3(Au)
885.018+
Peptide + 2(dampa) + 2(PPh3) + 4(Au) + 4(H) 860.498+
Peptide + 4(dampa) + 2(PPh3) + 2(Au)
844.518+
Peptide + 4(dampa) + 2(PPh3) + 1(Au)
937.027+
820.028+
Peptide + 4(dampa) + 2(PPh3) + 2(H)
795.528+
Peptide + 2(PPh3) + 2(Au) + 2(H)
777.228+
690.979+
Peptide + 3(dampa) + 3(PPh3) + 2(Au) + H
765.019+

Observed m/z
944.097+
826.208+
916.097+
801.718+
712.749+
884.988+
860.498+
844.458+
937.097+
819.958+
795.468+
777.218+
690.979+
764.999+

Table 4.4. Products of the reaction between B and NCp7 identified by mass
spectrometry 24 hours after mixing.

In order to observe the effects of the bulky PPh3 ligand of the reactivity profile of complexes of
this form, one equivalent of B per zinc finger was incubated with NCp7. Immediately after mixing,
few identifiable products were observed (Figure 4.12). Peaks representing [Peptide-Au3-(PPh3)2]
(m/z = 916.0926 (7+)), [Peptide-Au3-(dampa)3-(PPh3)3] (884.6648 (8+)), and [Peptide-Au2(dampa)-(PPh3)-H] (761.2114 (8+)) were observed. Especially at this early timepoint, the product
configuration is difficult to predict, as the ligands may remain bound to the gold, or may have been
transferred onto the peptide.
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Figure 4.12. Interaction of B with NCp7 immediately after mixing.

Product Identity
Peptide + 2(PPh3) + 3(Au)
Peptide + 3(dampa) + 3(PPh3) + 3(Au)
Peptide + (dampa) + (PPh3) + 2(Au)

Theoretical
m/z
916.977+
884.638+
761.218+

Observed
m/z
916.967+
884.668+
761.218+

Table 4.5. Products of the reaction between B and NCp7 identified by mass
spectrometry immediately after mixing.

After 24 hours of incubation, a multitude of products were identified. The most intense signal
after 24 hours corresponds to the peptide with two equivalents of triphenylphosphine and three
equivalents of gold bound, [Peptide-(PPh3)2-Au3] (m/z = 916.0926 (7+), 801.7065 (8+), 712.7398
(9+)). The structure [Peptide-(PPh3)2-Au4] (m/z = 944.0854 (7+), 826.2005 (8+)) was also
identified. These structures do not contain the ligand dampa, and show that the triphenylphosphine
ligand may contribute to preventing the C-S transfer mechanism. In these products, it is possible
that the triphenylphosphine ligand has dissociated from the gold and bound to the protein in an P134

S transfer mechanism analogous to the C-S mechanism previously observed, but it is also possible
that the products are bound in a [Peptide-Au-PPh3] motif, in which the metal center is reduced to
gold(I) upon loss of the additional ligands. Some products were identified which retained the
ligand dampa. These products include [Peptide-(dampa)3-(PPh3)3-Au3] (m/z = 884.9809 (8+)),
[Peptide-(dampa)2-(PPh3)2-Au4] (m/z = 860.4858 (8+)), [Peptide-(dampa)4-(PPh3)2-Au2] (m/z =
844.4468 (8+)), [Peptide-(dampa)4-(PPh3)2-Au1] (m/z = 936.9445 (7+), 819.9527 (8+)), [Peptide(dampa)4-(PPh3)2] (m/z = 795.4580 (8+), 690.9666 (9+)), [Peptide-(PPh3)2-Au2] (m/z = 777.2117
(8+)), and [Peptide-(dampa)3-(PPh3)3-Au2] (m/z = 764.9870 (9+)). Of particular interest are the
signals representing [Peptide-(dampa)4-(PPh3)2] and [Peptide-(dampa)4-(PPh3)2-Au], which serve
to indicate that the P-S transfer mechanism, analogous to the previously reported C-S transfer
mechanism, is possible, as both of these products contain a greater number of equivalents of
triphenylphosphine than gold. However, in the studies with the small molecule models NAcCys
and GSH this transfer mechanism was not observed, which may indicate that P-S transfer is only
favorable if there is a large amount of steric bulk present around the site of reaction. Again, the
exact configuration of the products is difficult to predict and warrants further experimentation.
4.4 Conclusions
In conclusion, gold mediated transfer of C-donor and P-donor ligands to sulfur containing
biomolecules were observed in the study of complexes A and B with NCp7. Additionally, the
crystal structure of the previously unreported complex B is detailed, and shows that the
triphenylphosphine ligand is trans to the nitrogen of dampa, illustrating “transphobia” in the
formation of complexes of this nature. The gold mediated C-S and P-S transfer mechanisms
discussed herein offer new and interesting pathways for the targeting of zinc finger protein,
allowing for the covalent modification of residues vital to the biological function of the protein,
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and show that complexes of this form may provide a platform for the development of agents
capable of selectively targeting NCp7. As such, additional investigation into the structure activity
relationships of complexes of this form is warranted in order to tune the reactivity with, and
therefore selectivity for, zinc finger proteins such as HIV-NCp7.
4.5 Experimental Section
Materials
All reagents were purchased from Sigma Aldrich, and were used without further purification.
Complex A was synthesized according to previously published methods.20 The NCp7 zinc finger
(SNAIVKCFNCGKEGHIARNCRAPRKKGCWKCGKEGHQMKDCTERQAN,

zinc

coordinating residues highlighted in red) was a generous gift from Dr. Yangzhong Liu. Solutions
of NCp7 were prepared by dissolving NCp7 in water at concentrations of 1 mg/mL (184 µM), and
this stock was diluted as necessary.
Synthesis
Synthesis of [AuCl(dampa)(PPh3)](PF6) (B): Complex B was synthesized by an adaptation of
previously published methods. Complex A was dissolved in acetone. Triphenylphosphine () and
potassium hexafluorophosphate were added, and the reaction mixture was stirred for 16 hours. The
solvent was evaporated under reduced pressure, and the residue was taken up in dichloromethane.
The suspension was filtered, and the filtrate was evaporated to a small volume under reduced
pressure. Diethyl ether was added, causing precipitation of the white product (62.3 mg, 62.7%
yield). Elemental analysis (experimental(theoretical)) for C27H27NAuClF6P2: C: 41.61%(41.91%),
H: 4.27%(3.52%), N: 1.78%(1.81%). Diffraction quality crystals of B were grown by slow
evaporation of a solution of B in chloroform.

136

X-Ray Determination of Crystal Structure
Data collection for the single-crystal of B was performed at 100 K using a Rigaku MicroMax007 HF X-ray generator, an EIGER R 4M detector and an Oxford Cobra cryosystem with Cu - Kα
(λ = 1.54184 Å) radiation. Data collection, cell refinement and data reduction were performed
using CrysALIS PRO 1.171.40.4a (Rigaku OD, 2018). The structure was solved with the SHELXT
structure solution program using intrinsic phasing and refined as an inversion twin with SHELXL
in Olex2.29–31 All nonhydrogen atoms were refined anisotropically and hydrogen atoms were added
to the structure in idealized positions and refined according to the riding model. Molecular graphics
were generated using Mercury (v. 1.10).32 Searches on the Cambridge Structural Database (CSD,
v. 5.39) were performed in Conquest (v. 1.22)33 and Mercury. Crystallographic information of B
can be found in Table 4.6.
NMR Spectroscopy Studies
1

H and 31P NMR studies were recorded on a Bruker AVANCE III 400 MHz spectrometer. 1H

NMR samples were referenced to the resonances of the solvent, and

31

P NMR samples were

referenced to an internal standard of trimethylphosphate.
Mass Spectrometry Studies
Mass spectrometry studies were carried out on a Thermo LTQ-Velos mass spectrometer.
Complexes A and B were incubated with NAcCys and GSH in 1:1 molar ratios, and were incubated
with NCp7 at molar ratios of 1 equivalent of complex per zinc finger. Studies involving NCp7
were carried out at 10 µM concentrations in a solution of 10% methanol. Studies involving
NAcCys and GSH were carried out at 1 µM concentrations in a solution of 10% methanol. I both
cases, the spray voltage was 2.3 kV.
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Chemical formula

C27H27AuClNP·F6P·CHCl3

Molecular weight (g·mol-1)

893.22

Crystal system, space group

Monoclinic, Cc

Temperature (K)

100

a, b, c (Å)

25.1639 (3), 8.6579 (1), 17.0485 (2)

β (°)

120.552 (2)
3

V (Å )

3198.63 (9)

Z

4

μ (mm-1)

13.17

Crystal size (mm)

0.26 × 0.18 × 0.05

Tmin, Tmax

0.105, 0.809

No. of measured, independent and observed [I 53335, 5479, 5462
> 2σ(I)] reflections
Rint

0.052
2

2

2

R[F > 2s(F )], wR(F ), S

0.039, 0.103, 1.04

No. of reflections

5479

No. of parameters

382

No. of restraints

2

Δmax, Δmin (e·Å-3)

2.96, −1.29

Table 4.6. Experimental details for crystal structure determination and
refinement of B.
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4.7 Appendix
Supramolecular features of the [AuCl(dampa)(PPh3)](PF6) crystal structure
The crystal packing of [AuCl(dampa)(PPh3)](PF6) (Figure 4.13(a)) is mainly formed by nonclassical hydrogen bonding. Every fluorine atom of the PF6- counter ion is involved in hydrogen
bonds, some of which are described in Table 4.7 and shown in Figure 4.13(b). Interestingly, two
bifurcated hydrogen bonds motifs can be observed in this structure, one in which the chloroform
molecule acts as a double donor (C28—H28···F6iv and C28—H28···F1iv in Table 4.7) and the
other where F6 is a double acceptor (C7—H7A···F6iii and C8—H8B···F6iii in Table 4.7). The
chlorine atoms from the chloroform molecule are also acceptors of H-bonding from either H of
the triphenylphosphine ligand or the aryl ring from the dampa ligand (see C5—H5···Cl3ii in Table
4.7 as an example).

(a)

(b)
b
o

c
F1
F3

a
F4

F6

P2

F5
F2

Figure 4.13. (a) Packing of the crystal structure of [AuCl(dampa)(PPh3)](PF6), with view
along b axis and (b) the non-classical hydrogen bonds involving the PF6- counter-ion.
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D—H···A

D—H (Å)

H···A (Å)

D···A (Å)

D—H···A (°)

C4—H4···F3i

0.95

2.53

3.470(14)

170.3

C5—H5···Cl3ii

0.95

2.86

3.493 (14)

125.2

C7—H7A···F6iii

0.99

2.55

3.457(15)

152.2

C7—H7B···F5

0.99

2.45

3.198(16)

132.2

C8—H8B···F6iii

0.98

2.44

3.393(17)

163.2

C28—H28···F6iv

1.00

2.31

3.266(15)

160.1

C28—H28···F1iv

1.00

2.57

3.387(15)

139.1

[Symmetry codes: (i) x, −y+1, z+1/2; (ii) x−1/2, y−1/2, z; (iii) x, y−1, z; (iv) x+1/2, y−1/2, z.]
Table 4.7. Hydrogen bonding geometry of the [AuCl(dampa)(PPh3)](PF6) crystal.
Although π···π stacking interactions are absent in this crystal structure, a C—H···π
interaction helps the lattice formation along the b axis, as shown in Figure 4.14. The interaction
occurs between the C13—H13 donor of one of the phenyl rings of the triphenylhoshine and the
phenyl ring of the dampa ligand (C13—H13···Cg1v 2.85Å).
b

Cg1v

C13

a

H13

Figure 4.14. The intermolecular C–H···π interaction present in [AuCl(dampa)(PPh3)](PF6).
Displacement ellipsoids are drawn at the 50% probability level. [Symmetry code: (v) x, -1+y,
z.]
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Characterization Data

Figure 4.15. Far-IR characterization of A (bottom) and B (top).

Figure 4.16. 13C-NMR spectrum of A.
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Figure 4.17. 1H/13C-HSQC spectrum of A.

Compound B

Free PPh3

Figure 4.18. 1H-NMR spectrum of B (top) and free triphenylphosphine (bottom).
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Figure 4.19. Mass spectrum of B.
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Chapter 5: Differences in the Reaction Products of
Gold(I) and Gold(I) Complexes with a Short Peptide
Sequence
5.1 Introduction
The short model for the relevant binding sequence of the C-terminal zinc finger from the Sp1
transcription factor, ACPECP, was found to form the unique bridged species {ACPECP-2[Pt(en)]}
(en = ethylenediamine) upon a 1:1 interaction between [PtCl2(en)] and ACPECP1. Additionally,
ion mobility mass spectrometry studies were used to elucidate the site of interaction between the
gold(I) complex [(PEt3)AuCl] and the C-terminal zinc fingers of NCp7 and Sp12. In the case of
NCp7, the “gold finger” products formed were gold(I) crosslinks, and the coordinating residues
gave the products the forms [Cys36-Au(I)-Cys49] and [Cys39-Au(I)-Cys49]. The experimental data
for the interaction with Sp1 confirmed Cys5 as one of the gold-coordination sites, and either His20
or His24 as the second binding site, giving the final product the conformation [Cys5-Au(I)His20/24]2. This data shows that platinum(II) and gold(III) can coordinate similar peptide sequences
with different modes of binding. In order to expand this work to systems with gold(III) metal
centers, the interaction of the short peptide sequence ACPECP was interacted with gold(III)
complexes containing the tridentate chelating ligand diethylenetriamine, and these interactions
were compared to the interaction of ACPECP with the gold(I) complex [(PCy3)AuCl] (PCy3 =
tricyclohexylphosphine).
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5.2 Experimental
Synthesis

of

Chlorotricyclohexylphosphinegold(I)

([(PCy3)AuCl]):

Chlorotricyclohexylphosphinegold(I) was synthesized by methods adapted from the previously
published method3. Sodium tetrachloroaurate hyrdate (41.5 mg, 0.115 mmol) was dissolved in 500
µL ethanol. Tricyclohexylphosphine (70.0 mg, 0.250 mmol) was dissolved in 500 µL chloroform,
and the solutions were combined, resulting in the immediate precipitation of a white needle-like
solid. The reaction mixture was stirred for one hour. The white solid product was collected by
vacuum filtration and washed with acetone and diethyl ether. The product was dried under vacuum
and characterized by 1H-NMR and 31P-NMR. 1H-NMR (CDCl3, 400 MHz): δ 1.75, m. 31P-NMR:
δ 53.9, s. Yield: 25.4 mg, 41.5%.
5.3 Results
The mass spectrum of a 1:1 mixture of [AuCl(dien)]2+ and ACPECP showed signals
representing both oxidized peptide, indicative of the formation of a disulfide bond across the
cysteine residues, and the gold bridged species, in which a single atom of gold is bound between
the cysteine residues. The products of the reaction with [Au(N-Medien)(1-MeCyt)]3+ are the same
as the products of the reaction with [AuCl(dien)]2+. In both cases, product formation occurs much
more rapidly than was observed when ACPECP was interacted with platinum(II) species. In both
cases, the signal for the oxidized peptide is significantly stronger than the signal observed for the
gold-coordinated species. This may be due to the small number of peptides between the cysteine
residues, which could result in a distance too short to easily form the linear coordination geometry
that is preferred by gold(I). The signal representing the gold bound species is seen at m/z = 813.15,
indicating that the gold(III) metal center is reduced to gold(I) upon coordination, which results in
the loss of two protons from the total mass.
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The mass spectrum of a 1:1 mixture of [(PCy3)AuCl] and ACPECP also resulted in the
formation of both oxidized peptide and the gold-bridged species. Additionally, signals representing
the products of ligand scrambling, as observed in previous studies with gold(I)-trialkylphosphine
complexes, were observed4. The signal representing the gold bridged species is seen at m/z =
815.17, indicating that coordination to the cysteine residues occurs without reduction of the gold(I)
metal center.
5.4 Discussion
Interaction of one equivalent of three gold complexes, [AuCl(dien)]2+, [Au(N-Medien)(1MeCyt)]3+, and [(PCy3)AuCl] with one equivalent of the short peptide ACPECP was investigated
by mass spectrometry. The binding properties of gold complexes with ACPECP is worthy of
investigation, as ACPECP is the polynucleotide binding sequence of the C-terminal zinc finger of
Sp1. The investigation of gold complexes as zinc finger proteins has been undertaken, but the
differences in the reaction mechanisms between gold(I) and gold(III) complexes have not been
thoroughly studied. The oxidation of the peptide sequence, observed at m/z = 617.20 (1+), is
indicative of disulfide bond formation. Oxidized peptide is observed unilaterally upon interaction
of gold complexes with zinc finger proteins4–6. In the case of this short model sequence, the
oxidation takes the form of disulfide bond formation across the two cysteine residues. In order to
maintain oxidation/reduction balance, the oxidation of the cysteine residues is likely coupled to
the reduction of the metal center.
The gold bridged oxidized peptide is where differences in the products between the reaction
with gold(I) and gold(III) complexes can be observed. Both of the gold(III) complexes that were
investigated formed a gold bound product observed as a signal at m/z = 813.15 (1+). Conversely,
the product of the interaction with the gold(I) complex formed a gold bridged species observed as
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a signal at m/z = 815.17 (1+). The difference in mass to charge ratio of 2.02 is indicative of two
additional protons present on the product of the reaction with gold(I). This difference is caused by
the ligand substitution reactions on the gold(I) metal center without reduction. Conversely, the
lower observed mass to charge ratio after interaction of the gold(III) complexes is the result of the
loss of two protons, which indicates that the metal center was reduced from gold(III) to gold(I)
upon binding. The oxidation of the peptide is likely the result of disulfide bond formation. In order
for disulfide bond formation to occur, the reduced metal center must bond to a different location
on the peptide chain, such as an amine or carboxylate moiety. This result is further evidence that
tuning the electronic properties of the metal center can allow for fine-tuning of the reactivity with
proteins.

Figure 5.1. Mass spectrum obtained from a 1:1 mixture of [AuCl(dien)]2+ and ACPECP.
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Figure 5.2. Mass spectrum obtained from a 1:1 mixture of [Au(N-Medien)(1MeCyt)]3+ and ACPECP.

Figure 5.3. Mass spectrum obtained from a 1:1 mixture of [(PCy3)AuCl] and ACPECP.
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Chapter 6: General Conclusions
Up to 10% of the human genome codes for zinc finger proteins. The diverse set of functions
of zinc finger proteins makes them an excellent candidate for study, and a number of different zinc
fingers have been identified as potential targets for chemical intervention. In the case of NCp7, the
development of a selective inhibitor has the potential to make significant progress in the treatment
of HIV. This is due to the high conservation of NCp7, as well as the high number of viral life cycle
processes in which it is involved. A selective inhibitor of NCp7 would prevent the interaction
between NCp7 and its natural polynucleotide substrate. The most promising strategy for
preventing this interaction is the modification of the zinc coordination sphere, resulting in the
ejection of zinc. Zinc ejection has been shown to inhibit the recognition of NCp7’s natural substrate
and causes noninfectious virions.
While many examples of complexes, both organic and inorganic, that eject zinc from NCp7
have been described, a complex that achieves zinc ejection with a satisfactory degree of selectivity
has not been developed. To this end, inorganic complexes with a “formally substitution-inert”
coordination sphere have been investigated. These complexes contain an NCp7 recognition
element in the form of a nucleobase or N-heterocycle. In theory, a substitution-inert complex that
utilizes a structural element that imparts selectivity for the “essential” tryptophan residue could
undergo electrophilic attack at a nearby zinc-coordinating cysteine residue while still being a weak
enough electrophile to avoid unwanted side reactions by leveraging the proximity of the cysteine
and tryptophan residues.
In order to expand upon the previously studied series of gold(III) complexes of the form
[Au(dien)(N-heterocycle)]3+, and to complete the series of isoelectronic and isostructural
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platinum(II), palladium(II), and gold(III) complexes containing 1-methylcytosine as a ligand, the
complex [Au(dien)(1-MeCyt)]3+ was investigated. This previously unreported complex, along
with the analogous [Au(N-medien)(1-MeCyt)]3+ were investigated for their ability to interact with
N-acetyltryptophan and the C-terminal zinc finger of NCp7 as models for the full protein. The
enhancement of the π-π stacking ability of the aurated complexes over the free N-heterocycle is in
agreement with the enhancement observed for the previously studied N-hetercyclic ligands. For
the first time, formation of oxidized dimerized peptide was observed by mass spectrometry,
indicating that these complexes possessed a reactivity profile distinct from the previously
investigated complexes containing other N-heterocyclic ligands. Additionally, a vital feature of
the substitution-inert complexes is the stabilization of the gold(III) oxidation state using the AuN4
coordination sphere. As expected, the stabilization observed for the complex [Au(dien)(1MeCyt)]3+ follows the trend of ligand basicity, and the reduction potential is intermediate between
the previously studied DMAP and 9-EtGua analogs.
In order to further build upon the structure activity relationships of AuN4 complexes and to
investigate the effect of additional steric hindrance on the interactions with NCp7, gold(III)
complexes with the chelates BPMA and Me-BPMA were synthesized. These complexes were
synthesized alongside the isostructural and isoelectronic platinum(II) complexes in order to make
direct comparisons. The upfield 1H-NMR shifts observed metalation of the chelating are more
pronounced in the case of the gold(III) than in the platinum(II), highlighting the increased
electronegativity of gold(III) relative to platinum(II). Both the gold(III) and platinum(II)
complexes possessing the MClN3 coordination sphere are capable of ejecting zinc from the zinc
finger structural motif, but the gold(III) analogs eject the central zinc atom much more rapidly than
the platinum(II) analogs. Finally, while the PtN4 complexes, which incorporate an N-heterocycle
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creating a “formally substitution-inert” complex, were stable and isolable, the gold(III) analogs
were too unstable to be isolated, likely due to the increase of steric hindrance imparted by the
chelating ligand. In addition to the steric demands of the BPMA chelate, the electronic demands
in going from sp3 in the case of dien to sp2/sp3 may also contribute to the instability of the AuN4
complexes.
In the future, it would be possible to expand the investigation of AuN4 complexes as NCp7
inhibitors. The complexes studied in this work have not been able to match the inhibitory ability
of

the

current

lead

organic

compounds

such

as

4-(Hydroxymethyl)-6-phenyl-2,3-

dihydropyridazin-3-one, which act by competing with nucleic acids for binding to NCp7, similarly
to the previously studied platinum(II) complexes. The leading platinum(II) candidate for further
development is [Pt(dien)(xanthosine)]2+. The aurated analog of this complex has not yet been
investigated. Therefore, in order to further study gold(III) complexes as inhibitors of NCp7, and
to develop a complex capable of rivaling the current organic compounds in NCp7 inhibitory
activity, the complex [Au(dien)(xanthosine)]3+ should be investigated.
A significant portion of the current investigation into gold coordination-complexes centers
around the incorporation of a gold-carbon bond. Organometallic gold complexes possess a
reactivity profile distinct from the previously investigated AuClN3 and AuN4 complexes. In order
to extend this observation to the NCp7 system, the complex [AuCl2(dampa)] and the
triphenylphosphine analog [AuCl(dampa)(PPh3)]1+ were investigated. Upon interaction with Nacetylcysteine and glutathione, these complexes showed the ability undergo a C-S transfer,
resulting in cysteine arylation. This interaction draws parallels to the mechanism by which N-ada
repairs methylated DNA by transferring the methyl group onto a zinc-bound cysteine residue in a
zinc finger motif. The triphenylphosphine complex displays “transphobia” and was synthesized
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with the intent of blocking the chloride cis- to the gold-carbon bond. The ability of the
triphenylphosphine complex to undergo cysteine arylation despite lacking the cis-chloride
disproves the previously published assertion that the cis-chloride was essential for the carbonsulfur transfer to take place. The reactions of the complexes with the dampa chelate highlight the
increased flexibility of the dampa chelate relative to the previously investigated benzylpyridine
chelate, and it is possible that the reductive elimination mechanism releases the gold(I) complex
[(PPh3)AuCl], which has been previously studied as a zinc ejector.
Additionally, it was found using the short model peptide ACPECP that gold(III) complexes
undergo reduction when cysteine residues are oxidized, resulting in disulfide bond formation. This
is in contrast to gold(I) complexes, which are not reduced and likely bond so as to bridge the
cysteine residues. This coordination motif is likely more favorable in the case of gold(I), as the
linear geometry of the metal coordination sphere is maintained.
This work serves to expand the knowledge of how the steric and electronic environment of the
gold metal center affects the interactions of gold coordination complexes with NCp7. This work
was undertaken with the goal of selectively inhibiting NCp7, and although a complex that did not
display reactivity towards sulfur-containing biomolecules such as glutathione was not achieved,
the information gained by the investigation of these complexes will aid future investigators to
develop a complex that displays the desired reactivity profile. Gold(III) complexes with an
organometallic chelate have emerged as prime candidates for development of a selective NCp7
inhibitor. Two approaches to impart selectivity could be: substitution of the labile chloride ligands
in order to create a substitution-inert gold coordination sphere and the incorporation of an NCp7
recognition element. This recognition element will likely take the form of a nucleobase or Nheterocycle, which is capable of recognizing the “essential” tryptophan residue of NCp7 through
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a π-π stacking interaction. This interaction will bring the metal center into close proximity with
the highly nucleophilic zinc-bound cysteine residues, which will allow interaction with a weak
electrophile.
In order to continue the investigation of organometallic gold(III) complexes as potential
selective inhibitors of NCp7, a library of complexes could be developed. The bidentate
organometallic chelating ligands dampa and bnpy offer a well-studied starting point, while
tridentate organometallic chelating ligands such as m-xylylenediamine offer a lower number of
labile chloride ligands which must be replaced in order to impart selectivity. The bnpy analog of
the triphenylphosphine complex [AuCl(dampa)(PPh3)]1+ could be investigated to determine if
cysteine arylation is possible at the trans position in a complex with the less flexible, more
sterically hindered bnpy chelate. Additionally, the use of other trialkylphosphine groups could be
used to build a library of complexes with the same organometallic chelates, but different steric and
electronic environments. Ideally, through careful selection of a combination of a tryptophan
recognition element and a steric and electronic environment around the metal center, a selective
inhibitor of NCp7 can be developed.

159

Appendix: Recovery of Platinum and Gold from
Laboratory Waste
Introduction
The high cost of platinum makes the recovery of platinum from residual laboratory waste a
worthwhile endeavor.
Experimental
Platinum Recovery
Platinum was recovered from residual laboratory waste in the form of K2[PtCl4] by methods
adapted from the previously published method1.
Liquid platinum waste was adjusted to a pH of 14 using solid sodium hydroxide. The basic
solution was heated to evaporate the solvent. The solid residue was transferred to a porcelain
dish, and any solid platinum waste was added. The combined solids were heated with a Meker
burner until the color became black/grey and no smoke was observed. During heating, the solid
was stirred in order to ensure even burning. In order to remove any residual salts, the solid/ashe
mixture was washed with water until the filtrate was colorless and clear. The remaining solid was
suspended in aqua regia (30 mL/1 g solid), and gently heated. The solution was filtered, and this
process was repeated two additional times (for a total of three extractions). Potassium chloride (1
g/1 g ash) was added to the combined aqua regia filtrate. The volume of the solution was reduced
to 1/3 of the original volume by gently heating the solution. The solution was cooled to induce
the crystallization of a yellow solid (K2[PtCl6]). The yellow solid was collected by filtration,
washed with cold water, and dried.
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The recovered K2[PtCl6] was suspended in water (10 mL/g). A solution of hydrazine
dihydrochloride (0.1 g/mL) was added dropwise at 60°C until the solution changed from yellow
to red. Once the solution was red, addition was stopped and the temperature was increased to
85°C for 30 minutes. The solution as cooled to room temperature, and any remaining K2[PtCl6]
was removed by filtration. The red filtrate was evaporated under reduced pressure, yielding
K2[PtCl4] as a red solid.
K2[PtCl4] was recrystallized by dissolving the solid in a minimal amount of hot water,
removing any residual K2[PtCl6] by filtration while the solution was hot, and evaporating the
solvent under reduced pressure.
Gold Recovery
Gold recovery was attempted by evaporating liquid gold waste to dryness. The solid was
dissolved in aqua regia, and the solution was heated to 70 °C for two hours. The solution was
filtered, and the filtrate was concentrated to 1/3 original volume. The solution was extracted with
butyl diglyme. 5 wt% oxalic acid was added, and the solution was heated to 75 °C for two hours.
The resulting gold(0) was collected by filtration.
Results
40 g of K2[PtCl4] was recovered. 1.5 g of gold(0) was recovered.
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